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Abstract 
In various neurodegenerative diseases, including Alzheimer’s disease, progressive 
supranuclear palsy, Pick’s disease, and corticobasal degeneration, the deposition of fibrils 
composed of misfolded tau protein is observed.  Recent evidence suggests that tau fibrils 
transfer between cells and spread throughout the brain, underscoring the significance of 
fibril propagation.   
Six tau isoforms exist in the adult human brain that can be grouped into 4-repeat 
(4R) tau and 3-repeat (3R) tau based on the presence or absence of the second of four 
microtubule binding repeats.  We demonstrate in vitro that seeded fibril growth, a 
prerequisite for the spreading of the tau pathology, is crucially dependent on the isoform 
composition of individual seeds. Seeds of 3R tau and 3R/4R tau recruit both types of 
isoforms.  Seeds of 4R tau recruit 4R tau, but not 3R tau, establishing an asymmetric 
barrier.  Conformational templating of 4R tau onto 3R tau seeds eliminates this barrier, 
giving rise to a new type of tau fibril.  
Tau fibrils formed in vitro routinely utilize polyanionic molecules as cofactors to 
stimulate nucleation.  A broad set of negatively charged cofactors, including nucleic 
acids, polypeptides, and glycosaminoglycans were applied to induce fibril assembly.  
Utilizing electron paramagnetic resonance (EPR) spectroscopy, we found that the core 
structure of the fibril is conserved, regardless of cofactor used.   Additionally, we 
assessed whether a cofactor provides a role in tau aggregation beyond inducing the initial 
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nucleation events, and observed that the presence of a cofactor is needed for fibril 
propagation to be sustained.  The cofactor-fibril interaction was investigated, revealing 
that cofactors are bound to the fibril and that the basis of the interaction is electrostatic.  
Cofactor binding is dynamic, as introduction of an alternative cofactor was shown to 
result in exchange with the bound cofactor.  
Protein misfolding cyclic amplification (PMCA) is a tool used for the detection of 
dilute concentrations of prion fibrils.  We have successfully applied this concept towards 
the amplification of tau fibrils for the first time and demonstrated that fibrils can be 
amplified, even when diluted by several orders of magnitude. 
These findings provide basic mechanistic insights into the seeding, propagation, 
and diversification of tau fibrils.  Importantly, we demonstrate that cofactors are not only 
of consequence for inducing nucleation events, but decorate the fibril and provide a 
critical role in fibril propagation. 
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Chapter 1: Introduction 
1.1 Protein misfolding and amyloids 
1.1.1 Misfolding and disease 
The 3-dimensional structure of a protein has been shown to be governed by its 
primary structure (1, 2).  While linear strands of most proteins fold into highly structured 
native states, there are also proteins whose native states are devoid of structure in large 
regions or the entirety of the protein and are considered to be intrinsically disordered (3).  
The association of disordered proteins with various neurodegenerative diseases has been 
well documented, with aggregated forms of the natively disordered protein found 
accumulated in the form of fibrillar aggregates (4, 5).  Among these disordered proteins is 
the microtubule-associated protein tau (6, 7) that is found deposited as misfolded 
aggregates in Alzheimer’s disease brain.  The appearance of these aggregates has 
instigated an effort to better understand the structure of aggregates as well as the 
mechanisms responsible for their initiation and growth. 
Protein aggregation is the result of a protein misfolding to a conformation other 
than its native soluble state.  For folded proteins it has been suggested that the main event 
leading to aggregate formation is the destabilization of the native state, which results in 
an unfolded intermediate that is then more prone to aggregation (8, 9).  As intrinsically 
disordered proteins already lack secondary or tertiary structure, the process of unfolding 
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is not required and instead the already unfolded protein can switch more directly to the 
conformation of the aggregate.   
Protein misfolding is a common event that can have deleterious consequences. 
Within the cell there exist corrective mechanisms to ameliorate the effects of misfolded 
proteins, namely the recognition and degradation of the potentially harmful conformation 
through the proteosome (10) or the intervention by the chaperone system that allows a 
misfolded conformation to fold properly (11, 12).  Misfolded proteins that are not 
remedied can pose serious risks to the cell and provide the basis of any one of a number 
of diseases referred to as protein conformational disorders (13).  How a misfolded 
conformation can induce a harmful effect is not entirely understood and may vary 
according to disease and disorder.  A general paradigm is that misfolded proteins can 
contribute to the disease pathogenesis by providing a toxic gain of activity (i.e. the 
misfolded protein is toxic) or that the harmful effect stems from a protein losing its 
natural function as a consequence of misfolding.  For misfolded conformations that lead 
to intermolecular associations and aggregation, it is possible that the protein aggregates 
produce the toxic gain or loss of function that is witnessed in disease (4, 13).  Although 
the causative link of these aggregates to the progression of disease is not conclusive, the 
appearance of these protein aggregates has warranted extensive investigation 
nevertheless.    
1.1.2 Amyloid structure of aggregates in disease 
The deposition of aggregates containing misfolded proteins is observed in 
numerous neurodegenerative diseases other than Alzheimer’s disease, and includes 
Parkinson’s disease, and Huntington’s disease, Amyotrophic lateral sclerosis, as well as 
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the transmissible spongiform encephalopathies (14).  Common to all these protein 
aggregates is a conserved amyloid structure (14) and a fibrillar morphology (15, 16).  
Structurally characteristic of amyloid fibrils is a conserved cross -structure, in which 
fibrils are composed of stacked protein strands hydrogen bonded as -sheets and aligned 
perpendicular to the long axis of the fibril (17, 18).  Additionally, different amyloids 
share a general property used for their structural identification, namely the ability to bind 
and enhance the fluorescence of dyes such as thioflavin T and thioflavin S (19).  As to the 
specific composition of amyloids, the protein involved varies considerably depending on 
disease.  In Alzheimer’s disease, proteins of tau and amyloid-beta (A) are observed as 
amyloid deposits (20), while in Parkinson’s disease and the spongiform encephalopathies, 
amyloids are composed of α-synuclein and prion proteins, respectively (14).   Despite the 
potential to form a conserved structure, the proteins found to assemble into amyloids 
have no general sequence homology, nor any overall resemblance in native structure (14, 
21).  The general paradigm of amyloid aggregation was that the occurrence was rare and 
was only specific to a small group of proteins (around 20) that were found to assemble 
into such structures observed in disease.  However, the SH3 domain of 
phosphatidylinositol 3-kinase, and acylphosphatase—proteins whose aggregation is not 
observed in disease—were shown to be capable of forming amyloid aggregates under 
non-physiological conditions (22, 23).  Furthermore, myoglobin, a well-structured 
globular protein that lacks -sheets in its native state, was induced to form fibrillar 
aggregates under specific conditions (24).  It is believed that almost any protein possesses 
the capacity to form amyloid fibrils, given the right environmental conditions (23). 
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1.1.3 Model of amyloid formation 
The pathway that describes the conversion of the monomeric protein or 
polypeptide species into their assembled amyloid counterparts has long been considered 
crucial for the therapeutic intervention of amyloid diseases.  Despite decades of research, 
however, a comprehensive and generally accepted mechanism that describes the step-
wise assembly of amyloid fibrils has remained elusive (25, 26).   The course by which 
intra and intermolecular associations occur towards the polymerization of fibrils proceeds 
via a nucleation dependant mechanism (27, 28).  Observations of the kinetics of a 
polymerization reaction reveals a long lag phase where little or no assembly is shown to 
occur, followed by a dramatic acceleration and then gradual plateau of amyloid growth 
(Figure 1.1).  The events related to the lag phase are not fully understood, but are defined 
by the time required for nucleation to occur.  Nucleation of fibrils during the lag phase 
can be divided into two general processes described as primary or secondary nucleation 
(29, 30).  Primary nucleation involves the conversion of monomer into nuclei that are 
competent for fibril growth, while secondary nucleation can be attributed to fibril 
breakage that leads to additional nucleation competent species (more fibril ends) (29-31).  
Explanations for the events preceding the formation of competent nuclei range from 
conformational rearrangements of monomers and the intermolecular assemblies of 
monomers into oligomeric species (25-27).  In the case of oligomer formation it is 
thought that the successive assembly of monomers occurs until nuclei are formed that are 
capable of adding monomers to form a fibril.  Once the nuclei are formed, the addition of 
monomers will proceed to elongate fibrils, presumably by the addition of monomer at the 
ends of the fibrils.  As the lag phase leading up to the elongation phase is dependent on 
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the slow formation of nuclei (29), the introduction of competent nuclei would be 
expected to bypass the nucleation event and lead directly to the elongation of the fibril.  
This phenomenon is observed when preformed fibrils are added to monomers as seeds, 
resulting in the abolishment of the lag phase and the direct induction of fibril growth (27, 
28). 
 
Figure 1.1:  Aggregation kinetics of amyloids.  Observed in the aggregation of 
amyloids is a lag phase which is dependent on the time required for nuclei to form.  
Nucleation is a prerequisite for fibril growth, and can be circumvented by the addition of 
fibril seeds. 
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1.2 Tau and disease 
1.2.1 Tau aggregates are found in disease 
Alzheimer’s disease is form of dementia that is estimated to affect up to 24 
million people worldwide (32). In Alzheimer’s disease there are two fundamental 
pathological hallmarks that are observed in the diseased brain.  Lesions of aggregated 
material are found both extracellularly as neuritic plaques and intracellularly as 
neurofibrillary tangles (NFTs) (20, 33).  The chief component of neuritic plaques was 
identified as amyloid aggregates composed of A protein (34, 35).  Studies focusing on 
the intracellular NFTs revealed an abundance of fibrils composed of paired helical 
filaments that were capable of being stained with congo red dye, which like A suggested 
an amyloid structure (36).  The proteinacious composition of these NFTs began to be 
elucidated when it was shown that antibodies to tau were also selective to neurofibrillary 
tangles (37).  Furthermore, antibodies to fibrils are selective to tau and vice versa, 
suggesting that the fibrils in NFTs contain tau (38, 39).  The finding that the protein 
purified from NFT derived fibrils shared the amino acid sequences found in tau 
confirmed that the fibrils are in fact composed of tau (40).  Importantly, the prevalence of 
lesions composed of tau is not specific to just Alzheimer’s disease, as tau lesions are 
found in other neurodegenerative diseases and disorders as well.  Combined there are 
more than 20 diseases besides Alzheimer’s where tau lesions are central to the pathology, 
termed tauopathies, and include progressive supranuclear palsy, Picks’s disease, 
coricobasal degeneration, and Down’s syndrome (41, 42).  
The protein composition of fibrils has long been known, but what role the fibrils 
play in disease is not well understood.  For instance, in what manner the fibrils are 
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responsible for the progression of disease has been a matter of debate.  Alternative 
perspectives of the impact of tau fibrils even speculate that the fibrils could provide a 
protective role by recruiting and therefore reducing species that are toxic to the cell (43).  
While the specific role of tau species in disease is not known, the contribution of tau 
towards disease has been verified by genetic data. In frontotemporal dementia and 
Parkinsonism linked to chromosome 17 (FTDP-17), mutations in the tau gene have been 
implicated to disease suggesting a hereditary basis. Additionally, tau gene mutations have 
been linked to an increase in risk of developing other tauopathies including Pick’s disease 
and progressive supranuclear palsy (41).  Combined, these cases linked to tau gene 
mutations indicate that tau dysfunction can be attributed to disease.  Evidence that links 
tau fibrils to disease includes the observations that the distribution of NFTs is not 
random, but can be differentiated into six successive stages known as Braak stages.  Also, 
the advanced Braak stages observed occur with concomitant cases of dementia (44).    
Further evidence that indicates a relationship between tau fibrils and disease include the 
observation that the severity of dementia caused by Alzheimer’s disease correlates with 
the amount of NFTs present (45).  These findings have helped to shed light on the disease 
pathology and suggest that tau fibrils contribute to disease progression. 
1.2.2 Tau fibril propagation 
Tau fibrils have been associated with the development of disease, and therefore it 
is important to better understand the mechanisms behind the misfolding of monomeric 
tau into fibrils.  The aggregation of monomeric tau into fibrils was suggested to occur 
through a nucleated assembly mechanism.   With the addition of fibrils formed in vitro or 
extracted from Alzheimer’s disease brain, monomeric tau can be recruited onto fibril 
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seeds (46).  In another study it was shown that monomeric tau elongated on fibril seeds 
and adopted the conformation of the seed in a templated mechanism (47).   Earlier 
paradigms regarding the tendency of tau to misfold and form fibrillar aggregates 
proposed the event to occur autonomously in cells and therefore the effect that fibrils 
could have on neighboring cells was not thought to be of great importance (48).  With 
recent findings it has been proposed that tau fibril formation may not occur independently 
within each cell, but that fibrils having nucleated in one cell could propagate and spread 
to neighboring cells.  The ability of fibrils to recruit monomer when introduced to cells 
was shown by Nonaka et al. when fibrils transfected into cells overexpressing tau 
resulted in the aggregation of the endogenous monomer (49).  Additionally, Frost et al. 
demonstrated that tau aggregates are capable of being taken up by cells; that intracellular 
aggregates can transfer between co-cultured cells; and that once cells are transfected with 
tau aggregates, the misfolded state is propagated in the endogenous tau population (50).  
In other studies it was shown that cells are capable of internalizing fibrils and that the 
endogenous tau is recruited as aggregates resembling NFTs (51, 52).  When 
characterizing the tau species that are internalized by cells it was revealed that small 
aggregates and short fibrils (10-100 µm) are taken up while monomer and larger fibrils 
are not (53).      
Propagation of tau fibrils and the misfolded tau pathology has also been 
demonstrated in the brains of mice.  When insoluble extract containing fibrils from the 
mouse brain was injected into healthy mouse brain, the healthy mouse’s brain developed 
a fibrillar tau pathology that spread from the site of injection (54).  Similarly, when brain 
extracts from humans who had died from various tauopathies was injected into mouse 
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brain, the formation of tau lesions was induced (55). In other mouse models, pathogenic 
misfolded tau originating in the entorhinal cortex has been shown to spread to 
neighboring brain regions resulting in the aggregation of the local monomer (56, 57).    
From these findings it is clear that the propagation of tau fibrils is not limited to 
the cell or brain region of origination, but instead tau fibrils are found to spread 
intercellularly via undefined mechanisms.  From cell and animal models it has been well 
established that misfolded tau in the form of fibrils can exert profound effects when 
introduced, as the misfolded state of the fibril can be passed onto the endogenous tau 
population. 
1.2.3 Structure of fibrils 
Investigation of the structural features of tau aggregates reveals a commonality to 
amyloid structures, as tau fibrils also possess an ordered cross- structure. The spacing 
between the stacked strands perpendicular to the long axis of the fibril occurs every 4.7 Å 
(58) (Figure 1.2A).  Analysis of tau fibrils (Figure 1.2B) by electron microscopy and 
atomic force microscopy reveal tau fibril structure is actually diverse, with variations 
observed with respect to fibril width and twist periodicity (59).  While atomic resolution 
structures have yet to be elucidated, studies using in vitro formed fibrils indicate that the 
 strands of the fibril are arranged parallel to one another with the same residues in 
different strands stacking in-register (60-62) (Figure 1.2C).   The arrangement for how 
the -sheets of a fibril pack with respect to one another has been difficult to determine 
and only recently have experiments been implemented that are capable of providing  
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distance constraints within a strand.  From these distance measurements the first models 
have been created that provide structural insights into how the -sheets pack within 
fibrils (63). 
 
 
Figure 1.2:  Structure of tau fibrils.  (A)  Stacked -sheets of tau strands are arranged 
perpendicular to the long axis of the fibril, with 4.7 Å spacing between strands.  (B)  
Electron microscopy image of tau aggregates reveal fibrillar morphology akin to other 
amyloids.  (C)  Strands within a -sheet are arranged parallel with side chains (yellow 
circles) stacked in-register. 
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1.2.4 Tau function and properties 
The primary function of tau was first elucidated when it was observed that tau 
was found associated with microtubules, and furthermore that the polymerization of 
tubulin into microtubules was reliant on this associated protein (64).  Later it was 
revealed that tau provided a role not only for initiating formation, but also for the growth 
of microtubules through elongation (65).  Tau has been shown to bind and support 
microtubules (66, 67), while also modulating microtubule dynamics, both accelerating 
the rate of polymerization and inhibiting depolymerization (68). 
In determining what region of tau is responsible for the binding of microtubules it 
was demonstrated that it is actually a relatively small portion of the protein that 
associates.   This binding region consists of semi conserved sequence repeats of around 
30 amino acids located towards the carboxyl terminus of the protein (69-71).  Using 
constructs composed of these microtubule binding repeats, it was shown that the repeats 
alone are capable of aiding tubulin assembly into microtubules (72).  Interestingly, the 
core of the fibrils is located within the microtubule binding repeats (60, 62, 73), with the 
remaining majority of the protein remaining unstructured and providing a peripheral 
“fuzzy coat” (74, 75).   
The complexity of the study of tau protein is amplified in that there are 6 isoforms 
expressed in the adult human brain (76).   Tau can have either 3 or 4 microtubule binding 
repeats depending on alternative splicing of exon 10 in the tau gene (77) (the individual 
microtubule binding repeat sequences along with the largest full tau sequence, htau40, are 
depicted in Appendix A).   Towards the N-terminus of tau there exist one, two, or no 
insert regions, and between the N-terminal inserts and microtubule binding repeats is a 
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proline rich region (70).  The differences in the number of N-terminal inserts and 
microtubule binding repeats present within tau are the basis for the variations between the 
tau 6 isoforms (Figure 1.3).   
 
Figure 1.3: Tau isoforms.  Six isoforms are produced in the adult human brain.  
Variations occur in the N and C termini of the protein.  Either 0, 1 or 2 N-terminal inserts 
can be included (gray hatched), while differences in C-terminus arise from the inclusion 
of either 3 or 4 microtubule binding repeats (shaded gray).  Tau can be described based 
on the number of microtubule binding repeats as either 3R or 4R tau. 
 
 
Additional variations in tau also occur due to post-translational modifications 
including phosphorylation, glycosylation, and proteolysis (78, 79).  The phosporylation 
of tau is believed to be a key event in the progression of Alzheimer’s disease.   In 
diseased Alzheimer’s brain hyperphosphorylation has been shown to occur at 45 possible 
sites compared to only 10 sites in normal control brains (80, 81).  Additionally, tau is 
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found phosporylated in disease brain 3-4 times the extent than tau in normal brain (82).  
The effects of hyperphosphorylation are not fully understood, but have been shown to 
cause a decrease in microtubule affinity and a reduced capacity to promote microtubule 
assembly (83, 84).  It has been suggested that when tau is detached from microtubules 
due to hyperphosporylation, aggregation is more probable due to the increased tau 
concentration in the cytosol, which ultimately leads to the formation of fibrils found in 
disease.  This hypothesis is supported by experiments that have shown that 
hyperphosphorylated tau extracted from Alzheimer’s disease brain is capable of 
aggregating at low concentrations within a short time-period (85).  Also, 
hyperphosporylation of tau has been found to occur prior to the earliest detection of any 
tau aggregation in disease (86).  Despite this evidence it has not been substantiated 
whether phosphorylation is necessary for tau aggregation in disease.  Additionally, 
hyperphosphorylation of tau has even been shown to inhibit aggregation of tau, 
suggesting a protective role from aggregation (87).  Contrary to the proposed opinion that 
hyperphosporylation leads to the fibrillization observed in disease, evidence has been 
shown by recombinant protein that phosporylation is not a prerequisite for tau 
aggregation (88, 89). While the phosporylation of tau is a hallmark of Alzheimer’s 
disease, the hyperphosphorylation events that have been linked to Alzheimer’s also have 
been shown to occur during normal embryonic development, suggesting that by itself 
phosphorylation does not result in aggregation and disease progression (90).   
1.2.5 In vitro tau fibrils and polyanionic cofactors 
The deposition of misfolded tau into ordered fibrillar aggregates is observed in 
disease, but can also be recapitulated in vitro, as recombinant tau monomer has been 
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shown to assemble into fibrils (89, 91, 92).  The commonality between fibrils found in 
disease and those formed in vitro is reflected by comparable structural properties.  
Specifically, fibrils derived from disease and fibrils formed in vitro have both been 
shown to have a common cross- structure with 4.7 Å spacing between strands (58).  
Also, the morphological appearance of in vitro fibrils is indistinguishable from fibrils 
found in disease (93).  While recombinant tau is capable of forming fibrils consistently 
under relatively simple conditions, as compared to conditions within a cell, an interesting 
stimulant utilized for the process to occur is the addition of negatively charged cofactors, 
including the glycosaminoglycan heparin (94).   The manner by which a cofactor 
facilitates the transition of monomeric tau to highly structured aggregates is not fully 
understood.  One general observation is that the cofactor greatly enhances the nucleation 
process needed for fibril growth to occur.  Speculated mechanisms describing how a 
cofactor might induce aggregation include neutralizing the repulsive electrostatic 
interactions within tau that inhibit aggregation (95), and binding to multiple tau 
monomers to increase local concentrations that lead to aggregation (96).  Interestingly, 
hyperphosphorylated tau extracted from Alzheimer’s disease brain is capable of 
assembling into fibrillar aggregates without the addition of a polyanionic cofactor (85).  
One explanation for the effect observed from the hyperphosphorylation of tau is that the 
negative phosphates introduced neutralize the basic side-chains within the microtubule 
binding region and stimulate aggregation (84).   
Polyanionic cofactors bind to tau monomer (97-99) and cofactors can induce 
secondary structure formation (98) in a normally unstructured monomer.  With this in 
mind, it is possible that the cofactor binding to the monomer allows the monomer to 
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adopt a conformation that is more amenable to nucleation and growth of fibrils.  
Considerations beyond the effects on nucleation, is whether the cofactor has any role in 
the growth or sustainability of the fibril once nucleation has occurred.  How the cofactor 
interacts with the mature fibrils has been difficult to determine, and reports are 
conflicting on whether the cofactor binds and is therefore included within the fibril (98, 
100-102).  Questions like these are important for providing a more comprehensive 
understanding of tau fibrils, as the role of the cofactor could have significant influences 
on how these fibrils propagate, as well as modulate the conformations of fibrils produced. 
When considering the possible roles a cofactor may have on tau fibrils, it is 
important to recognize the various types of molecules shown to be capable of facilitating 
aggregation.  Sulfated glycosaminoglycans such as heparin (Figure 1.4A), heparan 
sulfate, and dextran sulfate have been shown to induce fibril formation in vitro (92, 103).  
Importantly, observations that uncharged glycosaminoglycans do not stimulate fibril 
formation, and that increases in glycosaminoglycans sulfonation results in increases in 
fibril formation indicate that the ability of a cofactor to aid in fibril aggregation is 
dependent on the negative charges of the molecules (103).  Incubating tau with other 
biological polymers such as nucleic acids (104) and polyglutamate (Figure 1.4B) (105) 
has also been shown to lead to the formation of fibrils.  As these polymers contain 
negatively charged functional groups that are not sulfates (i.e phosphodiesters and 
carboxylates), the requirements for polymers that could act as cofactors for fibril 
formation would be expected to be less discriminating and simply require the presence of 
multiple negative charges.   Furthermore, functional cofactors are not limited to 
negatively charged polymers, as arachidonic acid, phosphatidylserine, and alkyl sulfate 
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and sulfonate detergents, also induce tau aggregation (106, 107).  Interestingly, in these 
cases the facilitation of aggregation appears to proceed through the formation of micelles 
and liposomes (107). 
17 
 
Figure 1.4:  Heparin and polyglutamate cofactors.  (A) Heparin sulfate derived from 
porcine intestinal mucosa consists of a major disaccharide unit that is homogenously 
sulfonated and a minor unit that is heterogeneously sulfonated (108).  (B)  Polyglutamate 
peptide with varying lengths of glutamate units. 
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1.3 Description of research 
In the work described here, the misfolding of tau monomer into fibrils was 
investigated.  Previously, our group had shown that fibrils can form that are 
compositionally distinct based upon the number of microtubule binding repeats present in 
tau.  Fibrils composed of 4R tau, 3R tau, or mixed 3R/4R tau all have been shown to have 
a parallel, in-register arrangement of their -strands (62).  However, whether fibrils are 
conformationally distinct according to composition was unknown.  In these studies we 
have compared the seeded growth of both 3R and 4R tau upon addition of the different 
fibril types and observed variations in seeding properties that can be attributed to 
differences in conformation.  In order to assess the seeding properties, we developed an 
intrinsic assay that utilizes the fluorophore acrylodan as a reporter.  From this developed 
assay we were able to specifically observe the recruitment of tau monomer when fibril 
seeds were added. 
The assembly of fibrils is dependent on the addition of a polyanionic cofactor to 
aid in the initial nucleation event.  Using a diverse set of polyanionic cofactors including 
nucleic acids and polyglutamate we induced fibril formation and characterized the 
resulting fibrils by EPR spectroscopy as well as by their seeding properties.  Furthermore, 
the effect of a cofactor beyond the nucleation events was investigated, revealing that 
cofactors are not only needed for the initiation of nucleation events, but also facilitate the 
growth, as determined from seeding experiments.  When studying the fibril-cofactor 
interaction we found that the cofactor is incorporated with the fibrils, but can be 
exchanged when another cofactor is introduced. 
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In the prion field the the amplification of undetectable quantities of prion 
amyloids is accomplished using a protein misfolding cyclic amplification (PMCA) 
method (109).  As described herein we have applied this amplification method for the 
first time to tau fibrils.  With our applied method we have demonstrated that fibrils 
diluted several orders of magnitude can be amplified through seeded assembly to levels 
that are then detectable.  This method is expected to be used for the amplification and 
study of fibrils derived from diseased brain, and could eventually be applied for 
diagnostic purposes. 
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Chapter 2: Methods 
2.1 Tau constructs 
Htau40 and htau23 were cloned in pET-28b plasmids (62).  Natural cysteines (in 
the second and third repeats), two in htau40 and one in htau23, were replaced with 
serines using site-directed mutagenesis with the QuikChange method from 
Stratagene/Agilent Technologies.  The tau constructs with the natural cysteines replaced 
are described as “cysteineless” tau.  In order to generate constructs containing the 
microtubule binding repeat regions and excluding the N and C termini, fragments of K18 
and K19 (110) were created and cloned into pET-28b plasmids at XhoI and NcoI sites.  
The introduction of unnatural cysteines to which labels could be attached was 
accomplished using site-directed mutagenesis. All sequences were verified by DNA 
sequencing.   
2.2 Transformation of tau DNA 
Approximately 1 µg of tau DNA (gene in pET-28b plamids) was added to 20 µl 
BL21-DE3 bacterial cells (Agilent) in 14 ml polypropylene tubes (BD Biosciences cat. # 
352059) and incubated at 4 °C for 30 minutes.  Tubes were then submerged in a 42 °C 
bath for 50 seconds and immediately placed on ice for 2 minutes.  800 µl of NZY+ (10 
g/L NZ-amine, 12.5 mM MgCl2, 12.5 mM MgSO4, 20 mM glucose) was added to 
sample.  Bacteria was then placed in a shaking incubator at 37 °C for 40 minutes and 
plated on an agar plate.   
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2.3 Expression and purification of tau 
Tau was expressed in BL21(DE3) competent cells (Agilent).  Overnight cultures 
were prepared by adding a bacterial colony or applying bacteria from a glycerol stock to 
LB Miller solution and allowing bacteria to grow for 15 hr at 37 °C.  Bacteria from 
overnight cultures (15ml) was added to 1.5 Liters of LB miller (Difco) and cells were 
grown at 37 °C until the OD600 reached 0.8-1.0, after which isopropyl -D-1-
thiogalactopyranoside was added for a final concentration of 1 mM.  Cells were further 
incubated for 3 ½ hours and pelleted at 3,000 g for 15 minutes.  Bacterial pellets were 
resuspended in 500 mM NaCl, 20 mM piperazine-N,N’-bis(2-ethanesulfonic acid) 
(PIPES), 5 mM ethylenediaminetetraacetic acid (EDTA), 50 mM 2-mercaptoethanol, pH 
6.5 buffer and stored at -80 °C until later purification.  Samples were heated to 80 °C for 
20 minutes, cooled for 5 minutes at 4 °C, lysed by sonication, and centrifuged at 15,000 g 
for 30 minutes.  To the supernatants, a 55% w/v addition of ammonium sulfate was 
added.  Samples were allowed to incubate for 1 hour with gentle rocking, after which 
samples were centrifuged at 15000 g for 10 minutes.  Pellets were taken up in dH2O with 
4 mM dithiothreitol (DTT), sonicated for 40 seconds, syringe filtered, and applied to a 
Mono S 10/100 GL cation exchange column (GE Healthcare) in 50 mM NaCl, 20 mM 
PIPES, 500 nM EDTA, pH 6.5 buffer.  Tau was eluted with a 50 mM-1 M NaCl gradient 
and fractions were analyzed by SDS PAGE.  Enriched fractions were further purified 
with a Superdex 200 size exclusion column in buffered solution (100 mM NaCl, 20 mM 
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris), 500 nM EDTA, pH 7.4).  Purified tau 
was pooled and precipitated overnight at 4°C with an added 4-fold volumetric excess of 
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acetone for constructs K18 and K19 or a 1-fold volumetric addition of methanol for 
constructs htau23 and htau40, with 5 mM DTT.  Precipitated tau was sedimented at 
11,000 g for 20 minutes, washed in acetone (K18 and K19) with 2 mM DTT or methanol 
(htau23 and htau40) with2 mM DTT and stored at -80°C.   
2.4 Acrylodan labeling of tau 
Precipitated tau (approximately 5 mg) was dissolved in 8 M guanidine 
hydrochloride.  Acrylodan (Invitrogen) was conjugated to a single introduced cysteine 
(Figure 2.1) by adding dye in a 10 fold molar excess and incubating in the dark for 1 hr.  
Unbound acryrodan and guanidine hydrochloride was removed by passing sample 
through a PD-10 desalting column (GE Healthcare) with 100 mM NaCl, 10 mM (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, sodium salt (HEPES), pH 7.4 buffer.  
Non-labeled, cysteineless tau was treated identically, with the exception that no 
acrylodan label was added.  Protein concentration of eluted tau was determined by the 
BCA method (Pierce). 
 
 
Figure 2.1:  Acrylodan labeling of tau.  Mutated cysteine 310 (unless otherwise stated) 
of tau was conjugated to fluorophore acrylodan. 
Acrylodan 
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2.5 Fibril seed preparation 
Fibrils were prepared by incubating 25 µM K18 or K19 (or mixture of 12.5 µM 
K18 and 12.5 µM K19 in the case of mixed fibrils) for 3 days under stirring conditions 
with the presence of 50 µM heparin (average molecular mass of 5,000 Da, Celsus, 
Cincinnati, OH).  Fibrils were cooled on ice for 15 minutes and 500 µL was sonicated 
with a microtip for 20 seconds using a Fisher Scientific Sonifier (150 Series).  
2.6 Seeded assay and fluorescence detection 
Monomeric tau was present at a concentration of 10 µM for K18 and K19, and 20 
µM for htau40 and htau23.  Monomer consisted of molar fractions of 98% cysteineless 
tau and 2% acrylodan labeled tau.  Acrylodan label was conjugated to a single cysteine 
positioned at amino acid 310, unless otherwise noted.  All reactions were carried out in 
100 mM NaCl, 10 mM HEPES, pH 7.4 buffer.  Reaction kinetics were initiated with a 2-
fold molar addition of heparin and a 3% molar addition of fibril seeds.  Temperature was 
maintained at 37 °C with a solid state Pelletier element.  Fluorescence scans were 
obtained using a Fluorolog 3 system (Horriba, Jobin) fluorometer, with the excitation 
occurring at 360 nm and the corresponding emission obtained at 400 to 600 nm.  
Excitation and emission slitwidths were set at 5 nm. 
For reactions that involve multiple steps of seeding, tau monomer and seed 
concentrations were provided at 25 µM and 8% per mol respectively at each step.  These 
concentrations were increased to enhance the rate of the reactions.  Reactions were 
allowed to progress for 1 hr. at 37 °C, and each reaction was sonicated to provide seeds 
for the subsequent reaction.  In the final seeding step of the multi-step procedure 3% 
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seeds were used with monomer concentrations at 10 µM for K18 and K19 and 20 µM for 
htau40 and htau23. 
2.7 Sedimentation of tau fibrils 
After the completion of fibril growth from the seeded reactions, protein 
aggregates were sedimented for 40 min at > 100,000 g. The pellets were taken up in equal 
volumes of gel loading buffer and applied onto a 15% SDS-PAGE gel.  Proteins were 
stained with Coomassie Blue and quantified by densitometry. 
2.8 Thioflavin T Seeding Assay 
  Fibril formation was monitored by the change in ThT fluorescence (3) upon ThT 
binding to tau fibrils. Reactions were carried out in a HEPES buffer (100 mM NaCl, 10 
mM HEPES, pH 7.4) at 37°C, with 5 μM ThT. Tau (10μM K18 or K19) was pre-
incubated for 5 min at 37°C, whereupon reactions were initiated with 3 mol % of 
respective seeds. All reactions contained 2-fold molar excess of heparin (average MW = 
5000) to monomeric tau. Fluorescence was measured using a Fluorolog 3 
spectrofluorometer (Horiba Jobin Yvon), with the excitation wavelength set at 440 nm 
and the emission wavelength set at 480 nm. The excitation and emission slit widths were 
5 nm. 
2.9 Recruitment of K19 monomer with ∆K280 K18 seeds 
Fibril seeds were formed combining 25 µM tau monomer with 50 µM heparin in 
buffer (100 mM NaCl, 10mM HEPES, pH 7.4), and allowing reaction to incubate at 25 
°C under stirring conditions for 3 days.  Fibrils were fragmented by sonicating 500 µL of 
sample for 20 seconds with a microtip sonicator.  For sedimentation experiments a 10% 
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molar addition of K18 WT or ∆K280 K18 seeds was added to 10 µM K19 WT monomer 
in buffer with 20 µM heparin, and incubated for 3 hours at 37 °C.  Samples were 
centrifuged at > 100,000 g for 30 minutes at 10 °C.  Pellets were resuspended with 40 µL 
1X SDS PAGE sample buffer and aggregated tau was assessed by SDS PAGE. 
2.10 Electron microscopy 
250-mesh carbon coated copper grids were placed on 10 µL drops of the 
incubated sample for 40 s, 30 s on 10 µL 2% uranyl acetate, and air-dried on filter paper.  
Samples were imaged with a Philips/FEI Tecnai-12 electron transmission microscope 
equipped with a Gatan CCD camera. 
2.11 Spin-labeling of tau monomer 
Purified mutants of K18 and K19 tau containing single cysteines were labeled as 
shown in (Figure 2.2).   Precipitated tau pellets were dissolved in 200-400 µL of 8 M 
guanidine hydrochloride.  An approximate 10-fold molar excess of [1-oxy-2,2,5,5-
tetramethyl-pyrroline-3-methyl]methanethiosulfonate (MTSL) spin label (Toronto 
Research Chemicals, Downsview, Canada) was added to tau and allowed to incubate for 
at least 1 hr.  Tau samples were then purified with a PD-10 column (GE Healthcare) to 
remove denaturant and unreacted spin label.  Concentrations of tau monomers were 
determined using the BCA method (Thermo Scientific).  
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Figure 2.2:  Spin-Labeling of tau.  A single cysteine covalently labeled with MTSL 
spin-label.   
  
2.12 Fibril formation and EPR measurement 
Spin-labeled tau was incubated with respective cofactor at room temperature for 3 
days under stirring conditions.  Fibrils were formed in buffered solution (100 mM NaCl, 
10 mM HEPES, pH 7.4) with poly(A) RNA (Sigma P9403) at 70 µg/ml and 35 µM tau.  
Poly(A) RNA size distribution was determined by agarose gel electrophoresis to be 0.2-
2.0 kb.  Additional reactions were carried out with poly(U) (Sigma P9528), double 
stranded poly(AU) (Sigma P1537), transfer RNA (Sigma R8759), and RNA from baker’s 
yeast (Sigma R650) with concentration ranges of 140-200 µg/ml RNA and 35-50 µM tau. 
Fibrils were centrifuged at > 100,000 g for 30 min., washed with buffer, and centrifuged 
for 10 minutes at > 100,000 g.  Sedimented fibrils were transferred into capillary tubes 
with a 0.60 mm inner diameter x 0.84 mm outer diameter (VitroCom CV6084-100).   
Samples were measured with a Bruker EMX spectrometer equipped with an ER 4119HS 
resonator.  Spectra were obtained with a scan width of 150 G and a microwave power of 
12 mW, and normalized according to total number of spins as compared with a double 
integration.  The EPR signal for residual spin-labeled tau monomer, < 0.5%, was 
subtracted from all spectra. 
MTSL 
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2.13 Size distribution of RNA 
The size distribution of poly(A) RNA was determined using agarose gel 
electrophoresis.  A 1% w/v agarose gel was cast containing 1 µg/ml of ethidium bromide 
and 600 µg of RNA was loaded.  The size range of the RNA was determined using a 
RiboRuler High Range RNA Ladder (Thermo). 
2.14 Kinetics of seeded reactions using RNA polyA 
Seeded aggregation kinetics were monitored as previously described using the 
intrinsic acrylodan based assay.  Fibrils were formed for seeded reactions by combining 
25 µM tau (K18 or K19) and 50 µg/ml of poly(A) RNA  (Sigma P9403) in buffered 
solution (100 mM NaCl, 10 mM HEPES, pH 7.4) and allowing reactions to proceed for 3 
days under stirring conditions.  Reactions were chilled on ice for 15 minutes and 
sonicated for 20 seconds to induce breakage of fibrils.  Fragmented fibrils were used as 
“seeds” to initiate aggregation of monomeric tau.  Total monomer concentrations for K18 
and K19 were 10 µM, with 98% of monomer containing cysteineless tau (cysteines 
replaced with serines) and 2% acrylodan labeled tau (acrylodan covalently linked to a 
cysteine at amino acid 310).  Reaction kinetics were initiated with the addition of 20 
µg/ml poly(A) RNA and a 10 % (seed to monomer) molar addition of fibril seeds.  
Kinetics were measured at 37 °C using a Fluorolog 3 fluorometer (Horriba, Jobin).  The 
excitation wavelength was 360 nm and the emission spectra were scanned from 400-600 
nm with a 5 nm excitation and emission slitwidth.  
 28 
2.15 Successive seeding reactions  
Multistep seeding reactions were designed with and without the addition of 
poly(A) RNA as a cofactor.  Initial reactions were prepared combining 25 µM K18 WT 
or K19 WT, 125 µg/ml RNA, and a 10% molar addition of fibril seeds.  Seeded reactions 
proceeded overnight, whereupon 500 µL was removed, sonicated on ice and used for the 
seeding of the subsequent reaction.  Each additional reaction (25 µM tau monomer) was 
seeded with a 10% molar addition of seeds and was incubated overnight with and without 
the addition of 125 µg/ml RNA.  Fibrils for each reaction were sedimented at >100,000 g 
for 30 min., pellets were washed with buffer (100 mM NaCl, 10 mM HEPES, pH 7.4) 
and centrifuged for an additional 10 min.  Pellets were taken up in sample buffer and 
analyzed by SDS PAGE. 
2.16 RNA binding to tau and exchange with heparin 
Tau fibrils of either K18 WT or K19 WT were formed with the addition of 25 µM 
monomeric tau, 50 µg/ml poly(A) RNA, and 10% (molar) fibril seeds in buffer (100 mM 
NaCl, 10 mM HEPES, pH 7.4).  Seeded reactions were inverted 3 times and incubated 
for 2hr at 37 °C. Resulting fibrils were sedimented for 30 min. at >100,000 g.  Pellets 
were dissolved in 60µL 2% w/v SDS and the total volume was brought up to 1250 µL 
with buffer.  To supernatant samples 2% SDS was added and total volume brought to 
1250 µL with buffer.  RNA contained in pellets and supernatants was determined using a 
Cary 100 Bio UV-Visible spectrophotometer.   
For heparin exchange experiments fibrils were formed as above mentioned and 
heparin (average molecular weight 5000, Celsus, Cincinnati, OH) was added for a final 
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concentration of 50 µM.  Samples were inverted 5 times and incubated further overnight 
at 37 °C.  Fibrils were sedimented, resuspended, and analyzed by UV-Vis as before.  
Minor absorbance due to tau protein was subtracted from all spectra. 
2.17 Fluorescent heparin binds to fibrils 
Fibrils of K18 and K19 were prepared by adding a 10% (molar) of respective 
seeds to 10 µM monomer and 50 µg/ml RNA poly(A) in 100 mM NaCl, 10 mM HEPES, 
pH 7.4 buffer.  Reactions proceeded for 2 hr at 37 °C.  Fluorescent heparin (Invitrogen 
H7482) was dissolved in PCR certified H2O (Teknova W3340) and centrifuged at > 
100,000 g for 10 min and any insoluble material removed.  Fluorescent heparin (average 
molecular weight 18,000) was added to fibrils for a final concentration of 15 µM.  
Samples were inverted 5 times and incubated overnight at 37 °C.  Samples were 
sedimented at 100,000 g for 30 minutes and the supernatants removed from fibril pellets.  
Pellets were dissolved with 60 µL 2% SDS.  A corresponding concentration of SDS was 
provided for supernatant samples.  Both pellets and supernatants were brought up to the 
same volume with reaction buffer and samples were analyzed by UV-vis spectroscopy.  
Absorbance of fluorescent heparin was determined in both pellet and supernatant at 490 
nm.  RNA present was determined by absorbance at 260 nm with minor contributions 
from fluorescent heparin being subtracted. 
2.18 Heparin binding to fibrils by anisotropy 
Binding of fluorescein-conjugated heparin (average molecular weight 18,000, 
Invitrogen H7482) was monitored using a Fluorlog 3 fluorometer (Horriba, Jobin) with 
an excitation wavelength of 480 nm and a measured emission of 516 nm.  Integration 
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times were set to 0.1 sec. and the excitation and emission slitwidths were set to 4 nm and 
8 nm, respectively.  Fluorescent heparin alone was measured for 5 min in buffered 
solution (100 mM NaCl, 10 mM HEPES, pH 7.4).  Tau fibrils (25µM tau, 50 µg/ml 
poly(A) RNA) were formed as aforementioned and added to heparin for final 
concentrations of 6 µM tau fibrils (total tau) and 250 nM heparin. 
2.19 Aggregation of tau fibrils at high temperature and subsequent cooling 
Aggregation reactions were carried out in HEPES buffer (10 mM HEPES, pH 7.4, 
0.1 M NaCl or 2.0 M NaCl). Total tau monomer concentrations were 10 μM, with a 
molar ratio of 98% cysteine-free (cysteines replaced with serines) and 2% acrylodan-
labeled tau (position 310 replaced with cysteine and labeled). Heparin (Celsus, 
Cincinnati, OH) when present was 20 μM. Stirring was utilized in all reactions to 
promote aggregation. The progression of fibrillization was monitored using a Fluorolog 3 
fluorometer (Horriba, Jobin). All reactions were allowed to proceed for 80 min at 343 K. 
Temperature was adjusted using a solid state Pelletier element. Upon cooling from 343 K 
to 275 K, samples were allowed to equilibrate and were then measured. Excitation of 
samples occurred at 360 nm with a 5 nm excitation and emission slit width.  
2.20 Inhibition of heparin-mediated fibril growth by high salt 
Tau fibrils were prepared by incubating 25 μM K18 or K19 with 50 μM heparin 
(10 mM HEPES, pH 7.4) for 3 days at 25 °C under stirring conditions. Fibrils were 
chilled on ice for 10 min and sonicated for 20 seconds to induce breakage. Monomeric 
K18 and K19 (10 μM; 98% cysteine free tau and 2% acrylodan labeled at position 310) 
were seeded with a 3% molar addition of sonicated fibrils composed of their respective 
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construct. Reaction conditions were maintained at 10 mM HEPES, pH 7.4 in the presence 
of low (0.1 M NaCl) or high (1 M NaCl) salt. Heparin was added in all reactions at 20 
μM. Assembly of tau monomers on fibril seeds was monitored by observing the shift in 
fluorescence maximum of acrylodan label. Excitation of label occurred at 360 nm with 5 
nm excitation and emission slit widths. 
2.21 PMCA of tau fibrils 
All reactions were carried out in Nunclon (237105) 96-well plates (Thermo 
Scientific) and covered with BioDot Microplate sealing tape (dot scientific #T393).  
Reactions containing tau monomer were carried out with 10 µM htau40 WT 
(cysteineless), 40 µM of heparin (Celsus, average MW = 5000), and 5 µM thioflavin T 
(Sigma T3516) in buffer (100 mM NaCl, 10 mM HEPES, pH 7.4).  Fibril seeds were 
prepared by incubating 1.4 ml of 25 µM K18 WT (or K19 WT) for 3 days or htau40 WT 
for 6 days in buffer with the presence of 50 µM heparin under stirring conditions at room 
temperature.  For seed dilution experiments, seeds were diluted in buffer with the 
presence of 40 µM heparin.  Fibril seeds (not inititally sonicated) were added to reactions 
prior to incubation or PMCA sequence and are present according to the molar percentage 
of seed per monomeric tau.  After reactions were covered with sealant tape, plates were 
covered with respective cover, and secured with sealed transfer pippetes to prevent plates 
from sinking in sonicator bath (see Appendix C).  Plates were placed in a water filled 
microplate horn (Q Sonica #431MPX), coupled to an ultrasonic processor (Q Sonica 
Q700).  Temperature of bath was regulated at 37 °C with a recirculating chiller (Q Sonica 
#4900).  PMCA was programmed to undergo cycles of PMCA with 5 second pulses at 
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5% amplitude, followed by 30 minutes of incubation at 37 °C (for one cycle).  After 
completion of PMCA cycles, plates were centrifuged at 1,650 g for 2 minutes at room 
temperature to remove liquid accumulated on cover.  Samples were analyzed by 
fluorescence using a Tecan Infinite M1000 microplate reader.  Spectra of samples were 
obtained using a 440 nm excitation wavelength and scanning the emission from 450 nm – 
530 nm with 5 nm excitation and emission bandwidths.  Quantification of tau aggregation 
was determined by thioflavin T emission at 480 nm.  For sedimentation experiments 
same samples were pooled and 1.3 ml was centrifuged for 30 minutes at > 100,000 g at 
10 °C.  Pellets were washed with 1 ml of buffer and dissolved in 75 µL of 1X SDS PAGE 
sample buffer and run on SDS PAGE. 
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Chapter 3: Seeding properties of 3R and 4R tau 
3.1 Development of fluorescence assay to monitor  3R and 4R tau seeding 
As there are 6 different isoforms of tau present—which include either 3 or 4 
microtubule binding repeats—the composition of tau fibrils with respect to isoform can 
vary.  Previously, our group studied tau fibril structure and determined that 3 
compositionally distinct fibrils can be formed, which include fibrils composed of 3R tau, 
4R tau, and fibrils that have both 3R and 4R tau integrated into the same fibril (62).   In 
order to better understand how microtubule binding repeats could affect fibril 
propagation, we wanted to devise a methodology that would allow us to monitor the 
recruitment of monomeric tau as it assembles onto fibrils.  To observe this monomer 
recruitment we formed fibrils of tau using heparin and applied ultrasonic perturbation to 
shear the fibrils into smaller fragments that could then be used to seed the aggregation of 
monomeric tau.  Constructs K18 and K19 were used that contained the region responsible 
for forming the core of the fibril and included either 4 or 3 microtubule binding repeats, 
respectively, while omitting the C and N termini (Figure 3.1).   The ability of these 
constructs to form fibrils had previously been demonstrated (96).  To monitor the 
recruitment of monomer onto seeds we developed a fluorescent-based assay that utilizes 
the environment sensitive dye acrylodan (111).  Acrylodan was cross-linked to a cysteine 
introduced at amino acid 310 in the third repeat.  As the third microtubule binding repeat 
is within the core of the fibrils (60, 62) it was expected that the acrylodan reporter at this 
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position would be buried in the hydrophobic region of the fibril which would result in a 
blue-shift in the fluorescence emission.  In all reactions acrylodan labeled tau was mixed 
with unlabeled cysteineless tau in a 1:50 molar ratio.  Sonicated fibril seeds (Figures 
3.2A,B) were added to monomer, and recruitment of monomer was monitored by 
observing the acrylodan fluorescence maximum.  Before the introduction of seeds, the 
fluorescence of the acrylodan attached to monomeric tau (both K18 and K19) was 
observed to have a maximum of 523 nm, indicative of a site that is exposed to a polar 
environment (112).  This accessibility to the surrounding aqueous environment is not 
surprising as tau monomer has been shown to be intrinsically disordered (6, 7).  Upon a 
3% molar addition of K19 seeds to K19 monomer, the acrylodan emission was drastically 
blue-shifted over time, demonstrating the aggregation of the monomer (Figure 3.2C).   
The shift in the reciprocal of the max was plotted as a function of time and revealed the 
elongation kinetics of K19 fibrils (Figure 3.2D).  Likewise, K18 seeds added to K18 
monomer produced a similar shift in emission that indicated the aggregation of the 
monomer (Figure 3.2E,F).  Importantly, without the addition of seeds no change in 
emission was observed.  This is expected as tau aggregation is characterized by a lag-
phase that reflects the time needed for nucleation to occur (46).  The concentration of 
seed used was shown to modulate the seeding efficiency for both K18 and K19 seeding 
reactions, as increasing the seed concentration from 2% to 8% resulted in accelerated 
seeding kinetics (Figure 3.3A,B).   These combined results demonstrate the recruitment 
of monomer by fibrils composed of the same protein.  Furthermore, we have 
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demonstrated that our acrylodan assay is capable of monitoring the aggregation of 
monomer as it is recruited onto fibrils composed of the same protein. 
In collaboration with Dr. Ayisha Siddiqua, tau seeding experiments were 
conducted and irrespective of researcher, identical seeding properties for 3R and 4R tau 
recruitment were determined (as will be discussed), indicating the robust nature in how 
these fibrils propagate according to variations in the microtubule binding repeat region. 
  
Figure 3.1:  Truncated constructs K18 and K19.  Constructs K18 and K19 are derived 
from the microtubule binding repeat region of full-length tau.  4R tau is represented by 
construct K18 and 3R tau by construct K19. 
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Figure 3.2:  Intrinsic tau seeding assay.  Electron microscopy images of fibrils of K19 
(A) and K19 (B) that were sheared by ultrasonication and used as seeds onto which tau 
monomer was grown.  (C) Addition of 3% K19 seeds to a mixture of monomers of 98% 
K19 and 2% K19_310A1 (total concentration: 10 μM) results in a shift in the emission 
maximum from 523 nm to 465 nm. Excitation: 360 nm, Emission: 400 nm – 600 nm. (D) 
The inverse wavelength of the emission maximum plotted as a function of time reveals 
the progression of K19-seeded aggregation. In the absence of seeds no aggregation is 
observed. (E) When K18 seeds (3%) are added to a mixture of K18 monomers (98% 
K18, 2% K18_310A1) a similar spectral shift as for K19-seeded reactions is observed. 
(F) The inverse wavelength plotted as a function of time reveals the progression of K18-
seeded aggregation. In the absence of seeds no changes are observed. Values represent 
mean ± s.d. (n = 3 experiments). 
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3.2 Cross-seeding of 3R and 4R tau 
Tau constructs K18 and K19 differ by the presence or absence of the second 
microtubule binding repeat (Figure 3.1).  In order to determine whether this variation in 
sequence would affect the conformation of fibrils, as determined by seeding properties, 
we carried out cross-seeding experiments that assessed the capability of 3R to grow on 
4R fibril seeds and 4R to grow on 3R fibril seeds.   Reactions were performed as 
previously described by introducing a 50 molar excess of monomeric unlabeled cysteine-
free tau to acrylodan labeled tau and adding the respective fibril seeds.  While K18 
monomers were capable of elongating onto K18 fibrils, K19 monomers were not (Figure 
3.4A).  The aggregation of self-seeding K18 fibrils was assessed by electron microscopy 
(EM), which confirmed the growth of long fibrillar aggregates (Figure 3.4B) that were 
Figure 3.3:  Effects of altering seed concentrations.  Seed concentration of (A) K18 added 
to K18 monomer and (B) K19 seeds added to K19 monomer were varied.  The kinetics of 
the monomer recruitment was monitored for each seed concentration used. 
 
 38 
distinguishable from the short K18 fibril seeds (Figure 3.2B).  EM images taken from 
attempts to grow K19 on K18 fibrils did not reveal any fibrils (Figure 3.4C), concurring 
with the kinetic data that K19 does not grow on K18 seeds. 
As K18 was not capable of seeding K19, we anticipated that likewise, K19 fibrils would 
be unable to cross-seed K18 monomer.  Surprisingly, K19 seeds introduced to K18 
monomer resulted in the aggregation of monomer (Figure 3.4D).  Notably, the growth of 
K19 monomer onto K19 seeds was more efficient than K18 on K19 seeds.  The 
aggregation of both K18 and K19 monomer was confirmed by EM (Figure 3.4E,F).   
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Figure 3.4: Asymmetric barrier for K18 and K19 cross-seeding. (A) Aggregation of 
K18 monomers (98% K18, 2% K18_310A1) and K19 monomers (98% K19, 2% 
K19_310A1) in the presence of 3% K18 seeds. (B) Electron micrograph of K18 fibrils 
seeded with K18. (C) Electron micrograph of K19 grown onto K18 seeds. (D) 
Aggregation of K19 monomers (98% K19, 2% K19_310A1) and K18 monomers (98% 
K18, 2% K18_310A1) in the presence of 3% K19 seeds. (E) Electron micrograph of K18 
grown onto K19 seeds. (F) Electron micrograph of K19 grown onto K19 seeds. Protein 
concentrations were 10 μM. All values represent mean ( s.d. (n = 3 experiments). 
 
By cross-seeding K18 and K19 we observed a barrier that prevents 3R tau from 
growing onto 4R tau fibrils.  To further test this barrier we added K18 seeds to K19 
monomer at concentrations 3 and 5 times those first used (Figure 3.5A).  Importantly, 
even at elevated seed concentrations K19 does not grow on K18.  To ensure that the 
inability of K19 to grow on K18 fibrils does not originate from acrylodan fluorophore 
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being attached at amino acid 310, we introduced the fluorophore at positions 317 and 322 
and assessed the ability of K19 to grow on K18 fibrils (Figure 3.5B).  As before K19 
does not grow on K18 fibrils, which indicates that the barrier observed is not a 
consequence of labeling the 310 amino acid position.  Thus, our acrylodan assay reveals 
an asymmetry in the cross-seeding of 3R and 4R tau, which allows fibrils of 3R tau to 
seed 4R tau, but prevents 4R tau fibrils from seeding 3R tau. 
 
Figure 3.5: Asymmetric barrier for K18 and K19 cross-seeding. (A) A robust barrier 
prevents growth of K19 monomers onto K18 seeds. Circles = 9% seeds, diamonds = 15% 
seeds. Growth of K18 monomers onto 3% K18 seeds is shown for comparison (triangles). 
In all samples acrylodan is attached to position 310. (B) K19 aggregation monitored 
through acrylodan-labeled constructs K19_317A1 (circles) and K19_322A1 (squares) 
indicates that regardless of which position is labeled, K19 does not grow onto K18 seeds. 
Growth of K18 onto K18 seeds (triangles) is depicted for comparison. In all cases 3% 
seeds are added to 10 μM monomers. 
 
3.3 Cross-seeding analysis by sedimentation 
Using our intrinsically based fluorescent assay as well as electron microscopy we 
were able to observe an asymmetric barrier between 3R and 4R tau.  In order to further 
validate our findings and provide an additional determination of the degree of 
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aggregation we employed an assay that would measure the insoluble aggregates obtained 
through seeded reactions.  After monomer was allowed to aggregate with the addition of 
seed, reactions were given a high speed spin to sediment any resulting fibrils formed.  
Pelleted fibrils were solubilized and applied on SDS PAGE gels, and the density of the 
resulting bands was quantified.  The fibrils recovered from these sedimentation 
experiments is in agreement with the results of the acrylodan kinetic assay.  K19 
monomer was shown to be recruited by K19 fibrils, but not by K18 fibrils (Figure 3.6A).  
Alternatively, K18 monomer aggregated both in the presence of K18 and K19 seeds, with 
K18 seeds resulting in considerably more aggregation, consistent with acryodan kinetics 
data (Figure 3.6B).  
 
Figure 3.6: Sedimentation of K18 and K19 fibrils.  (A) Sedimented fibrils of K19 were 
analyzed by 15% SDS PAGE (upper panel) and quantified by densitometry (lower 
panel).  (B) Sedimented fibrils of K18 were analyzed by SDS PAGE (upper gel) and 
quantified by densitometry (lower panel).  Protein concentrations were 10 μM. All values 
represent mean ± s.d. (n = 3 experiments).  
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3.4 Thioflavin kinetics 
The kinetics of cross-seeding 3R and 4R tau was determined using an intrinsic 
fluorescent based assay.  Traditional amyloid determination assays typically utilize 
extrinsic fluorescent dyes such as thioflavin T (113).  Thioflavin T unbound has 
excitation and emission maxima of 350 and 438 nm, respectively.  Upon binding to 
amyloid fibrils the fluorescence of the dye substantially increases with a concomitant 
shift in the excitation and emission to 450 and 482 nm, respectively (114).  The 
mechanism responsible for the spectral shifts and increased fluorescence is not fully 
understood, but appears to occur through the binding of the fluorophore, whose long axis 
runs parallel to the length of the fibril (113, 115-117).  The practicality of using thioflavin 
T to determine amyloid abundance is well documented.  When amyloids of the same 
protein are assessed under the same designated conditions, the fluorescence intensity of 
the binding dye is proportional to amount of amyloid available (105, 113, 114, 117).  In 
order to verify the kinetics demonstrating an asymmetric barrier between 3R and 4R tau, 
we employed thioflavin T as an extrinsic reporter.  The kinetics were similar to what was 
observed using the acrylodan assay, as K18 was able to grow on both K18 and K19 
seeds, but K19 only grew on K19 seeds (Figure 3.7A,B).  These results further confirm 
the asymmetric barrier observed in the previous experiments. 
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Figure 3.7:  Thioflavin kinetics of 3R and 4R cross-seeding.  (A) Seeded fibril growth 
monitored with Thioflavin T (5 μM). Changes in fluorescence intensity indicate that K18 
monomers grow onto K18 seeds, but that K19 monomers do not. (B) ThT fluorescence 
reveals growth of K19 monomers onto K19 seeds and reduced growth of K18 monomers 
onto K19 seeds. In all thiofavin experiments, 3% seeds are added to 10 μM monomers. 
All values represent mean ± s.d. (n = 3 experiments). 
 
3.5 Seeding full-length tau 
All our previous seeding experiments between 3R and 4R tau used truncated 
constructs K18 and K19 as monomers to be recruited.  Although these constructs contain 
the region that forms the core of the fibril, we wanted to determine whether there were 
any differences in the seeding properties if full-length tau was recruited.  Utilizing 
monomeric full-length tau of htau40 that contains all 4 microtubule binding repeats and 
htau23 that only contains 3 repeats (missing the second repeat) we repeated our acrylodan 
kinetic experiments.   Cysteine-free full-length tau was again mixed with a 50-fold excess 
to acrylodan labeled tau at position 310.  Monomer was added to fibril seeds composed of 
either K18 or K19 and the kinetics observed as before.  When K18 seeds were added to 
htau40 monomer, htau40 was efficiently recruited as evidenced by the aggregation 
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kinetics.  While an immediate shift in the emission maximum did occur, htau23 did not 
appear to grow efficiently on K18 seeds (Figure 3.8A).  The aggregation of htau40 into 
fibrils was confirmed by EM (Figure 3.8B).  No fibrils were observed when htau23 was 
used as monomer when EM images were taken (Figure 3.8C).  Next, K19 fibrils were 
used to seed full-length tau monomer.  In both htau40 and htau23, monomer was 
recruited (Figure 3.8D), reaffirming the asymmetric barrier between 3R and 4R tau 
observed for K18 and K19.  To ensure that aggregation occurred for both htau23 and 
htau40 EM images were taken after the reaction and confirmed the growth of fibrils for 
both types of reactions (Figure 3.8E,F).   
In our kinetic experiments we demonstrate that full-length tau is capable of being 
seeded by the addition of K18 or K19 fibrils and that the barriers are the same as for the 
truncated versions.   As in reactions where K18 and K19 were grown on fibril seeds, full-
length tau is recruited onto the fibril seeds, thus elongating the fibril.  To demonstrate that 
the aggregation of htau40 and htau23 does not originate due to nucleation events 
occurring within the time-window monitored, we prepared reactions of full-length tau 
where no seeds were added.  Without the addition of seeds, full-length monomer does not 
aggregate (Figure 3.9), substantiating that the growth of full-length (Figure 3.8) occurs 
due to recruitment by fibril seeds and not due to nucleation.  
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Figure 3.8: Templated growth of htau23 and htau40. (A) Aggregation of htau23 
monomers (98% htau23, 2% htau23_310A1) in the presence of 8% K19 seeds or 8% K18 
seeds.  (B) Electron micrograph of K19-seeded reaction. (C) Electron micrograph of 
K18-seeded reaction. (D) Aggregation of htau40 monomers (98% htau40, 2% 
htau40_310A1) seeded by addition of 8% K18 seeds or 8% K19 seeds.  (E) Electron 
micrograph of K18-seeded reaction. (F) Electron micrograph of K19-seeded reaction. All 
values represent mean ± s.d. (n = 3 experiments) 
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Figure 3.9:  Full-length tau monomer does not aggregate without seeds.  (A)  
Kinetics of htau23 without the addition of seeds.  (B)  Kinetics of htau40 without the 
addition of seeds.  All values represent mean ± s.d. (n = 3 experiments) 
 
As observed in our acrylodan assay, the addition of K18 seeds to htau23 monomer 
resulted in an immediate shift in the emission maximum (Figure 3.8A).  This shift was 
minor in comparison to htau40 growing on K18 seeds.  However, in order to determine 
whether this shift was the result of aggregation of htau23 we performed sedimentation 
experiments at the end of the reaction.  When htau40 was seeded with K18 a substantial 
amount of insoluble fibrils were recovered (Figure 3.10A), whereas K18 seeding htau23 
resulted in little or no fibrils (Figure 3.10B).   Alternatively, when K19 seeded hau40 and 
htau23 monomer, both full-length proteins were found to have aggregated (Figure 
3.10A,B).  These basic findings are in agreement with our kinetic and electron 
microscopy data that indicate an asymmetric barrier allows the cross-seeding of 3R fibrils 
to recruit 4R tau, but prevents 4R fibrils from recruiting 3R tau.  Therefore, it is evident 
that the seeding properties remain unchanged, regardless of using full-length tau 
monomer, or monomer composed of solely the microtubule binding repeats. 
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Figure 3.10:  Sedimentation of full-length tau fibrils. (A) Sedimented pellets were 
analyzed by 12% SDS-PAGE (upper panel) and quantified by densitometry (lower 
panel).  (F) Sedimented pellets were analyzed by 12% SDS-PAGE (upper panel) and 
quantified by densitometry (lower panel). 
 
3.6 Seeding with coassembled fibrils of 3R and 4R tau 
Previously, it was shown that 3R and 4R tau are capable of assembling into the 
same fibril [45].  We formed mixed fibrils of K18 and K19 and assessed the seeding 
properties. With similar kinetics both K18 and K19 were recruited (Figure 3.11A). Fibrils 
were confirmed by EM at the end of the reaction (Figure 3.11B,C).  These results 
indicated that fibrils of mixed 3R/4R tau recruit both 3R and 4R tau monomer, and do so 
with comparable kinetics. 
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Figure 3.11: Seeds of K18/K19 effectively template growth of K18 and K19. (A) The 
inverse wavelength plotted as a function of time reveals the progression of K19 and K18 
aggregation.  Values represent mean ± s.d. (n = 3 experiments). (B, C) Electron 
micrographs of K18 and K19 fibrils produced through K18/K19-seeded reactions, 
respectively. 
 
3.7 Cross-seeding 4R on 3R seeds creates new type of 4R tau fibrils 
Tau aggregation results in the intermolecular stacking of strands in a parallel and 
in-register manner; therefore, assembly of fibrils occurs by a template-assisted 
mechanism in which the assembling monomer would assume the conformation of the 
fibril (60).  As we have observed that 4R tau is capable of being recruited onto 3R tau 
fibril seeds, the question arose as to whether the resulting elongated fibrils of 4R tau 
would then be able to seed 3R tau.  When growing 4R tau on 3R tau fibrils it would be 
anticipated that the 4R tau monomer would adopt the conformation of the 3R tau seeds.  
As such, the resulting 4R tau fibrils would be expected to now be capable of recruiting 
3R tau monomer.  In order to test our hypothesis, we designed a 3 step seeding 
experiment.  In the first step, K18 was grown on seeds of K19.  In the second step K18 
(on K19 seeds) fibrils were enriched by carrying out 3 successive seeding and elongation 
cycles.  In the third step the enriched K18 fibrils were used to seed K19 monomers 
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(Figure 3.12A).  As was hypothesized, the K18 fibrils that were templated on K19 seeds 
were capable of seeding K19 monomer (Figure 3.12B, top trace).    The effect of the K19 
seeds that were used to seed K18 in the first step can be discounted as the concentration 
of K19 seeds was drastically diluted through the enrichment steps undertaken in the 
second step of the experiment.  The concentration of K19 seeds was diluted by 65,000 
fold to bring K19 seeds from a concentration of 2.00 x 10
-6
 M to 3.1 x 10
-11
 M.  At this 
concentration K19 seeds do not accelerate aggregation, and therefore the growth of K19 
monomer in the final step cannot be attributed to any K19 seeds carried over during the 
reaction sequence.  In order to verify the aggregation of K19 monomer into fibrils, EM 
images were taken at the end of the reaction (Figure 3.12C).  Importantly, when the 
multistep seeding procedure was carried out with K18 seeds being used initially (instead 
of K19 seeds), K19 was not capable of being recruited in the final step (Figure 3.12B, 
bottom trace).  To ensure that the templating experiment would provide the same result 
had full-length tau been used, htau23 monomer was used in the final step and shown to 
be recruited (Figure 3.13A, top trace).  EM was used to confirm the presence of fibrils 
(Figure 3.13B).  Again, when K18 seeds were used in the initial seeding step no growth 
of 3R tau monomer was observed (Figure 3.13A, bottom trace).  The above described 
observations are important as they demonstrate that the same protein, such as K18, can 
assemble into different fibril conformations.  The differences in the fibrils produced is 
dependent on the initial template the monomer is offered.  Furthermore, our observations 
indicate that the seeding properties are propagated over multiple generations of fibril 
elongation. 
 50 
 
 
Figure 3.12: Tau fibril diversification. (A) Experimental design of multicycle seeding 
reactions. (B) Aggregation of K19 monomers (98% K19, 2% K19_310A1) in the 
presence of 3% seeds (last step in A) monitored as a change in inverse emission 
wavelength over time (top trace). When instead of K19 seeds K18 seeds were present in 
the initial seeding step, no aggregation occurred (bottom trace). Values represent mean ± 
s.d. (n = 3 experiments). (C) Electron micrograph representing the end point of the top 
trace in (B). 
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Figure 3.13: Tau fibril diversification with full-length tau. A multi-cycle seeding 
procedure as outlined in Fig. 4A is used with the only difference that seeds (8 mol %) in 
final reaction are added to htau23 (20 μM) instead of K19. (A) Aggregation of this 
reaction (98% htau23, 2% htau23_310A1) is monitored as a change in inverse emission 
wavelength over time (red). When initial seeds in this five-step procedure are K18 and 
not K19 fibrils, aggregation does not occur (black trace).  Values represent mean ± s.d. (n 
= 3 experiments). (B) Electron micrograph representing the end point of the red trace in 
A. 
 
3.8 Mutations can affect recruitment of tau monomer by fibril seeds 
Our results indicate that 4R tau can assemble into at least two conformations, one 
of which is capable of recruiting 3R tau.  Frost et al has shown that conformational 
differences in fibrils can occur due to mutations in tau.   Specifically, fibrils composed of 
wild-type tau are conformationally distinct from fibrils containing the disease mutant 
∆K280 (47).  As we have demonstrated that conformational differences in fibrils can 
dictate the recruitment of monomer, we wondered whether fibrils formed from tau with 
the ∆K280 mutation, which are conformationally distinct from wild-type tau fibrils, 
might recruit monomer differently.  To determine this we formed fibrils with ∆K280 K18 
tau and assessed whether K19 monomer could be recruited.  When a 10% molar addition 
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of ∆K280 K18 seeds was added to K19 monomer and incubated we found that the K19 
monomer was recruited by the seeds, as determined by sedimentation experiments 
(Figure 3.14A).  K19 monomer without the addition of seeds did not sediment, and with 
the addition of K18 seeds only a marginal amount of K19 was observed in the pellet.  
Importantly, the ability of K18 ∆K280 to seed K19 is not due to K18 ∆K280 fibrils 
aggregating more efficiently that K18 WT, as the sedimented seeds of K18 WT and K18 
∆K280 seeds were found to be of comparable density.  Triplicate analysis of 
sedimentation experiments confirmed the ability of ∆K280 K18 seeds to recruit K19 
monomer (Figure 3.14B).  Growth of K19 on K18 ∆K280 seeds is furthermore supported 
by EM images taken after a K18 ∆K280 seeded reaction, revealing an abundance of long 
fibrils that can be clearly distinguished from the short and fragmented ∆K280 K18 fibril 
seeds (Figure 3.14C,D).  Additionally, we applied our acrylodan assay to assess whether 
K19 was recruited by ∆K280 seeds.  When ∆K280 K18 seeds were added to acrylodan 
labeled K19 monomer, the acrylodan emission was blue-shifted by approximately 50 nm 
(Figure 3.14 E), indicating a local environment of increased hydrophobicity that would 
suggest aggregation had occurred.  From these results we demonstrate that a single 
mutation (in this case a deletion) can alter seeding properties of tau.  The effects of 
mutations on the recruitment of monomer are further being investigated by Virginia 
Meyer.   
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Figure 3.14: ∆K280 K18 fibrils recruit K19 monomer.  (A) Recruitment of K19 WT 
by ∆K280 K18 seeds.   K19 WT (10µM) was grown on 10% seeds of ∆K280 K18 or K18 
WT fibrils with 20 µM heparin.  After 3 hours of incubation aggregates were sedimented, 
dissolved in 2% w/v SDS (to dissociate fibrils), and analyzed by SDS PAGE and (B) 
quantified according to band density of aggregated K19 monomer.   Values represent the 
mean ± SEM (n = 3).  (C)  EM image of K19 WT (10 µM) seeded with 10 % ∆K280 WT 
seeds after 3 hours of incubation at 37 °C.  (D) EM image of 25 µM or sonicated ∆K280 
seeds. Bars = 400 nm.  (E)  ∆K280 K18 seeds (10%) were added to acrylodan labeled 
K19 monomer (amino acid 310).  Emission is shown before addition and after addition 
with 2 hours incubation at 37 °C.  Excitation = 360 nm. 
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Chapter 4: Tau cofactors bind and sustain fibril propagation 
4.1 Fibril structure determination by EPR spectroscopy 
In previous experiments the structural core of tau fibrils had been elucidated by 
spin-labeling single-cysteines introduced throughout the microtubule binding repeats and 
measuring the labeled fibrils by EPR spectroscopy (60, 62).  In these studies heparin was 
utilized to initiate the aggregation of the fibrils.  As a cofactor such as heparin stimulates 
aggregation of tau by inducing nucleation, we hypothesized that the nucleation of tau 
with different cofactors could lead to variations in fibril conformations.  Previously, 
Kampers et al. had shown that RNA was capable of functioning as a cofactor to induce 
fibril formation (104).  We hypothesized that fibrils formed by RNA could have a 
different structural core than fibrils formed by heparin.  In order to compare the structure 
of fibrils formed with RNA to those with heparin we carried out EPR experiments.    
Tau monomer that is spin-labeled with MTSL gives a spectrum with 3 sharp lines 
that is indicative of high mobility (60) and is in line with tau monomer’s disordered 
structure.   The 3 lines observed are expected for an MTSL labeled sample.  Hyperfine 
splitting gives rise to lines that can be determined based on the equation 2nI +1, where n 
= the number of equivalent nuclei and I = nuclear spin.  For a radical such as MTSL, 
nuclei of 
14
N give n = 1 and I = 1, and therefore 3 lines are observed (118).    Tau fibrils 
formed with heparin, however, reveal a broad single-line spectrum, indicative of a 
structured core composed of parallel, in-register -strands (60).  Stacking of labels from 
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different tau molecules allows spin-exchange, leading to the loss of hyperfine structure 
(60, 119).  Here, we formed spin-labeled tau fibrils with polyadenylic acid (poly(A)) 
RNA and analyzed the fibrils by continuous wave EPR.   Fibrils of K18 or K19 were 
labeled at 6 different positions within the third microtubule binding repeat.  As was 
observed for fibrils formed with heparin, poly(A) RNA produced fibrils with single-line 
spectra (Figure 4.1), indicating a parallel, in-register arrangement of -strands at the third 
repeat.  These findings reveal that even when using an alternative cofactor such as 
poly(A), the third repeat of tau is highly structured.  Next, we assessed whether the ability 
to form ordered aggregates of tau was limited to RNA, or whether we could also use 
DNA.  Using polydeoxyadenylic acid (poly(dA)) we formed fibrils with spin-labeled tau 
as before and measured the fibril samples.  As was seen for RNA, all 6 sites measured 
produced single-line spectra for K18 and K19 (Figure 4.2).  Using poly(A) and poly(dA) 
we showed that purine-based nucleic acids were capable of producing highly ordered tau 
aggregates.  In order to determine whether pyrimidine-based nucleic acids could also 
form fibrils with a highly structured third repeat we applied polyuridylic acid (poly(U)) to 
spin-labeled tau (position 310) and again observed single-line spectra for both K18 and 
K19 (Figure 4.3A).  Furthermore, we characterized the fibrils formed using double-
stranded polyuridylic and polyadenylic acids (poly(AU)), transfer RNA extracted from 
yeast (tRNA), and total RNA from yeast.  All of these RNA species produced fibrils with 
single-line spectra (Figure 4.3A).  As we had demonstrated that a glycosaminoglycan 
(heparin) and a broad class of nucleic acids effectively promoted highly ordered 
aggregation of tau, we next tested whether polyglutamate (polyGlu) would also induce 
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the formation of highly ordered fibrils.  The application of polyglutamate had previously 
been shown to promote fibril assembly (105).  As was shown for heparin and nucleic 
acids, polyglutamate produces fibrils from spin-labeled monomer that provided single-
line spectra (Figure 4.3B).  Combined, these data reveal that the parallel, in-register 
structure of tau fibrils is conserved regardless of cofactor used. 
 
Figure 4.1:  Spectra of spin-labeled tau fibrils using poly(A) RNA.  Polyadenylic acid 
poly(A) was used to induce the aggregation of spin-labeled monomer into fibrils.  Spin-
labels were attached at 6 different sites (conjugated to introduced cysteines).  Fibrils were 
analyzed by EPR and single-line spectra were found to occur at each of the 6 positions 
within the third microtubule binding repeat for fibrils composed of both K18 and K19 
tau.   
150 G 
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Figure 4.2:  DNA produce ordered fibrils.  Polydeoxyadenylic acid poly(dA) was used 
to induced the aggregation of spin-labeled monomer into fibrils.  Spin-labels were 
attached at 6 different (conjugated to introduced cysteines).  Fibrils were analyzed by 
EPR and single-line spectra were found to occur at each of the 6 positions within the third 
microtubule binding repeat for fibrils composed of both K18 and K19 tau.   
150 G 
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Figure 4.3:  Nucleic acids and polyglutamate produce ordered fibrils.  (A)  
Polyuridylic acid (poly(U)), double-stranded polyuridylic and polyadenylic acids, transfer 
RNA (tRNA) and total RNA extracted from yeast and (B), polyglutamate (polyGlu) 
produce fibrils that are highly ordered as indicated from single-line spectra obtained from 
spin-labeled tau.   
150 G 
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4.2 Seeding properties of tau using RNA as a cofactor 
Previously when the seeding properties of tau fibrils were studied, we had utilized 
heparin as a cofactor to initiate nucleation (120).  Our findings showed that an 
asymmetric barrier exists between fibrils of 3R and 4R tau (see Chapter 3), and that 
conformational variability can exist in fibrils composed of the same isoform.  Although, 
parallel in-registry is preserved, fibrils formed in the presence of different cofactors could 
have different conformations.  We next wanted to test whether cofactors affect seeding 
properties of tau fibrils, as differences in the seeding properties would indicate changes in 
fibril conformation.  Using poly(A) RNA as a cofactor we formed fibrils of K18 or K19 
and assessed these fibrils’ competency to recruit K18 and K19 monomer.  When using 
K18 fibrils as seeds we observed the efficient recruitment of K18 monomer, but not K19 
monomer (Figure 4.4A).  When applying K19 fibrils to monomer, the recruitment of both 
K18 and K19 monomer was observed (Figure 4.4B).  However, the cross-seeding of K18 
with K19 seeds was far less efficient than K19 seeding K19.  From these results we see 
that the asymmetric barrier between 3R and 4R tau is recapitulated when applying 
nucleic acids for aggregation. Importantly, when K18 and K19 are incubated with 
poly(A) RNA, but with no seeds, aggregation does not occur (Figure 4.5), indicating that 
RNA alone was not responsible for tau aggregation observed in the seeding experiments.  
The seeding experiments presented here indicate the robust nature of the seeding 
properties of tau, as the asymmetric barrier was observed even when using an alternative 
cofactor. 
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Figure 4.4:  Seeding properties of 4R and 3R tau using poly(A) RNA.  Seeding of 
K18 and K19 monomers with a 10% molar addition of (A) K18 seeds or (B) K19 seeds.  
Total monomer concentrations were 10 µM (98% WT, 2% acrylodan labeled_310A1), 
with 20 µg/ml of poly(A).  All values represent mean ± s.d. (n = 3 experiments). 
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Figure 4.5:  Aggregation does not proceed without addition of seeds.  Acrylodan 
assay of the kinetics of K18 and K19 (10 µM) fibril formation with the addition of 
poly(A) RNA, but without seeds.  All values represent mean ± s.d. (n = 3 experiments). 
 
4.3 Size distribution of poly(A) RNA 
Based on our EPR measurements and seeded reactions poly(A) RNA is capable of 
producing tau fibrils. What sizes of poly(A) were used to facilitate tau aggregation was 
unknown.  As we utilized poly(A) extensively in previous and subsequent experiments, 
we wanted to characterize the size distribution present in the poly(A) sample.  Poly(A) 
RNA purchased from Sigma had previously been shown to contain broad length 
distributions of 0.2-6.0 kb (121).  To determine the size distribution of the poly(A) RNA 
used for our experiments we performed agarose gel electrophoresis with ethidium 
bromide staining.  From the agarose gel we found that the predominant distribution of 
poly(A) RNA ranged from 0.2-2.0 kb (Figure 4.6).  This indicates that the poly(A) RNA 
species was not a defined size, but instead was composed of a relatively broad length 
range. 
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Figure 4.6:  Size distribution of poly(A) RNA.  Poly(A) RNA size distribution was 
analyzed on a 1% agarose gel, cast with ethidium bromide.  For size determination a 
RiboRuler High Range RNA Ladder (Thermo) was used for comparison. 
 
4.4 Cofactors sustain growth of tau fibrils 
The aggregation of tau monomer into fibrils has been shown to proceed through a 
nucleation-dependant mechanism (46).  From our seeding experiments we have also 
shown that preformed fibrils added to monomer abolish the lag-phase attributed to 
nucleation, which also supports a nucleation-dependent mechanism for fibril formation. It 
was previously suggested that cofactors are only needed for the initiation of nucleation, 
and are not required for the subsequent elongation of the fibril (102).  If this model is 
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valid then once the nucleation event is initiated by the cofactor, the presence of the 
cofactor should no longer be necessary for the fibril growth through elongation.  To test 
whether the cofactor was needed for the propagation of the fibrils we created an 
experiment where multiple seeding steps were carried out (Figure 4.7A).  The sequence 
of the experiment consisted of five successive seeded reactions (cycles 1-5), whereby 
fibril seeds from the previous reaction were used to seed the aggregation reaction.  For 
our cofactor we again utilized poly(A) RNA.  In one set of reaction cycles poly(A) RNA 
was included (+cf), while in another set of reaction cycles poly(A) RNA was only 
included in the first reaction (-cf).  At the end of each reaction cycle the fibrils were 
sedimented and run on an SDS PAGE gel.  For reactions using either K18 or K19 the 
addition of poly(A) RNA in each of the five reaction cycles resulted in the continued 
propagation of fibrils (Figure 4.7B, left panel).  When the poly(A) RNA was omitted 
after the first reaction cycle the fibril propagation was reduced and eventually no fibrils 
were found to have sedimented (Figure 4.7B, right panel).  These results clearly 
demonstrate that cofactor was needed for the fibril propagation to be sustained. 
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Figure 4.7:  Cofactor sustains propagation of tau fibrils.  (A)  Multi-step reaction 
sequence for the propagation of tau fibrils.  Tau fibrils are propagated by the successive 
seeding of fibrils from one reaction to another.  In all reaction cycles tau monomer is 
present (25 µM) and the fibrils from the previous reaction are used as seeds to recruit 
available monomer.  In one reaction sequence, (+cf), poly(A) RNA cofactor is provided 
in all 5 reaction cycles, whereas in another reaction sequence, (-cf), poly(A) cofactor is 
only provided in the first reaction cycle. (B)  SDS PAGE gels of sedimented fibrils from 
the experiment using either K18 or K19.  The sedimented fibrils from each reaction cycle 
are shown with poly(A) RNA in all reactions (left panel), or with poly(A) RNA only 
included in the intial reaction (right panel). 
 
In the multi-step seeding experiment we observed a strong dependence of the 
propagation of the fibrils with the addition of cofactor.  In previous kinetic experiments 
using heparin as a cofactor (120), and the above described seeding experiments using 
poly(A) RNA as a cofactor (Figure 4.4), we had always included the cofactor with 
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monomer, to which seeds were added.  Based on the results from the multi-step seeding 
experiment (Figure 4.7), we would expect that when conducting a seeded reaction that 
there would be a significant difference in the seeding efficiency depending on whether a 
cofactor was included.  Using poly(A) RNA as a cofactor we carried out seeding 
experiments with and without the addition of cofactor (Figure 4.8).  Our kinetics data 
reflected the muti-step seeding experiment, showing for both K18 and K19 that without 
the addition of cofactor the fibril propagation is dramatically reduced.  Furthermore, as 
nucleation of fibrils was shown not to occur in the time-period observed (Figure 4.5), the 
growth induced by the addition of seeds can be fully attributed to the elongation of the 
fibril seeds and not due to the formation of new fibrils through nucleation.  
 
 
Figure 4.8:  Cofactor is needed for elongation of fibrils.  Acrylodan kinetics of seeded 
aggregation of K18 (A), or K19 (B) on respective seeds (10 % by mole).  Reactions were 
carried out with (20 µg/ml) or without the addition of poly(A) RNA. All values represent 
mean ± s.d. (n = 3 experiments). 
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4.5 Tau-cofactor interaction is electrostatic 
By observing the effect of the cofactor on seeding efficiency we had observed a 
strong dependence of fibril propagation on the presence of cofactor.  It could be expected 
that as the core of the fibrils contain a largely basic region, that a polyanionic cofactor 
would facilitate fibril growth through electrostatic interactions with the fibril core.  To 
demonstrate that interactions between two species occur via electrostatics, the application 
of high salt can be used (122, 123).  When binding occurs through oppositely charged 
surfaces the conditions of high ionic strength through the introduction of high salt is seen 
to be capable of abolishing these electrostatic interactions.  If the negatively charged 
cofactor facilitated fibril growth through oppositely charged electrostatic interactions 
with tau monomer or fibril, then it would be expected that here also elevating the ionic 
strength would reduce the fibril assembly.  We observed the self-seeding kinetics of K18 
and K19 fibrils (K18 fibrils seeding K18 and K19 fibrils seeding K19) in the presence of 
low (0.1 M NaCl) and high (0.5 or 1.0 M NaCl) salt.  When using poly(A) RNA as a 
cofactor low salt conditions allowed for the seeded growth of K18 and K19 fibrils, 
whereas when the concentration of salt was elevated the fibril growth was abolished 
(Figures 4.9A,B).  To see whether the inhibitory effect of high salt was also reflected 
when using a different cofactor we carried out the experiments using heparin instead.  As 
was observed for poly(A) RNA the introduction of high salt inhibited the fibril growth 
(Figure 4.9C,D).  These experiments indicate that the cofactor interacts with tau during 
the elongation of the fibril and that the interactions are electrostatic.  
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Figure 4.9:  High salt concentrations inhibit fibril elongation.  Acrylodan kinetics of 
seeded-aggregation with conditions of low and high salt.  (A)  Growth of K18 monomer 
on K18 seeds with 20 µg/ml RNA, and (B) growth of K19 monomer on K19 seeds with 
20 µg/ml RNA.  (C) K18 self-seeded growth with 20 µM heparin (D) K19 self-seeded 
growth with 20 µM heparin.  All tau concentrations were 10 µM.  All values represent 
mean ± s.d. (n = 3 experiments). 
 
4.6 Cold dissociation of tau fibrils 
Computational studies with our collaborators have indicated that at high 
temperature (340 K) -sheet-strand probability reaches a maximum (124).  The 
temperatures used for our aggregation reactions ranged from 25 °C to 37 °C.  In all of our 
experiments thus far we have provided cofactor for the nucleation of fibrils.  Whether 
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fibrils could be formed at higher temperatures conducive to -sheet-strand probability 
(340 K) without the presence of a cofactor was not known.  Using our acrylodan assay 
we monitored the fibril formation with and without the addition of heparin at 343 K.   
With the addition of heparin the aggregation was rapid, while without any cofactor the 
reaction proceeded slowly (Figure 4.10A).  At the end of the reactions sample was 
mounted on EM grids. EM images revealed fibrils formed with and without heparin.  
However, fibrils formed without heparin appeared to have disintegrated (Figure 4.10B).  
We reasoned that this disintegration could have originated from the temperature change 
as the fibrils cooled during the mounting procedure carried out at room temperature.  To 
test the temperature effects on tau fibril integrity we monitored changes in the emission 
spectra.  The acrylodan fluorescence blue-shifted during amyloid formation at 343K with 
and without heparin (although to a lesser extent) (Figure 4.10C,D).  After heating, the 
K18 solution was cooled to 275 K.  When heparin was added, cooling to 275 K resulted 
in an additional blue-shift in the acrylodan fluorescence, which could be attributed to a 
further maturation of the fibrils (Figure 4.10C).  However, when K18 fibrils without 
heparin were cooled to 275 K the main peak of acrylodan fluorescence red-shifted back 
to the original monomeric position (Figure 4.10D).  Meanwhile, the shoulder region 
between 400 and 450 nm increased, possibly indicating an increase in soluble oligomers.  
These experiments indicate that K18 can form fibrils without heparin at high 
temperatures, and when cooled the fibrils cold dissociate.  Fibrils formed with cofactor 
do not cold-dissociate suggesting that the heparin provides a stabilization role in 
preventing dissociation.   
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Figure 4.10: Heparin locks the tau protein K18 fibril and prevents its reversion. (A) 
Kinetics of fibril formation at 343 K in the presence (blue) and absence (red) of heparin, 
as determined by the shift of the emission maximum of acrylodan labeled tau. Values 
represent mean ± s.d. (n = 3 experiments). (B) EM images of fibrils formed at 343 K in 
the presence (left panel) and absence (right panels) of heparin. Two images are shown for 
fibrils formed without heparin. Bar = 200 nm. (C and D) Representative spectra of 
aggregation reactions in the presence and absence of heparin, respectively. Spectra of 
monomeric tau (green), after aggregation of fibrils at 343 K (blue), and when cooled to 
275 K (purple). Protein concentration = 10 µM. NaCl concentration = 0.1 M. The data 
indicate that heparin prevents tau fibrils from dissociating in the cold. 
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4.7 Cofactor binds to fibrils 
The cold dissociation experiments indicated that the introduction of a cofactor 
prevents fibril dissociation when cooled.  If the cofactor provides a stabilizing role it 
would be likely that the cofactor binds to the fibril.  To assess cofactor binding to fibrils 
we utilized poly(A) RNA as a cofactor for fibril formation.  After forming the fibrils with 
the RNA the insoluble fibrils were sedimented and pelleted fibrils were separated from 
supernatants.  The pellets were dissolved in 2% w/v SDS (to dissociate fibrils) and 
adjusted to the same volume as the supernatant with buffer and 2 % w/v SDS.  As RNA 
absorbs strongly in the UV region, we utilized UV-Vis spectroscopy to determine 
whether RNA was associated with the fibrils (pellet) or whether it did not bind 
(supernatant).  Absorbance contributions due to tau protein were negligible, as we 
utilized truncated constructs that contained only 1 tyrosine and no tryptophan residues.  
Spectra for the analysis of RNA bound to K18 revealed that a majority of the RNA was 
contained in the pellet, indicating that RNA binds to tau fibrils (Figure 4.11A).  The total 
RNA concentration used for these reactions was also analyzed and was found to be 
approximately equal to the sum of the RNA in the pellet and supernatant. Triplicates 
confirmed the binding of RNA to K18 fibrils (Figure 4.11B).  For K19 fibrils we also 
observed that a majority of the RNA provided is bound to the fibrils (Figure 4.11C,D).  
These findings indicate that the cofactor-tau interaction is not limited to monomer-tau 
during nucleation, but instead the cofactor binds and is a constituent of the fibrils. 
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Figure 4.11:  RNA binds to tau fibrils.  Tau fibrils were prepared incubating 25 µM tau 
with 50 µg/ml poly(A) RNA.  Sedimented samples were analyzed for poly(A) RNA 
contained in the pellet and supernatant.  The pellet was dissolved and fibrils dissociated 
using 2% w/v SDS.  Spectra for RNA contained in pellet and supernatant, and total RNA 
used, for (A) K18 fibrils and (B) K19 fibrils.  Absorbance of RNA for triplicate samples 
for K18 (B) and K19 (D) fibrils.  Values for (B) and (D) represent mean ± s.d. (n = 3 
experiments). 
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4.8 Cofactors can exchange on the fibril 
4.8.1 Cofactor exchange by sedimentation analysis 
In the case of poly(A) RNA we have shown that the cofactor binds to the fibril.  
We next wanted to determine whether once bound, if a cofactor was capable of being 
removed through the addition and exchange of another cofactor, or whether the cofactor 
binding was more permanent.  To determine this we formed fibrils with poly(A) RNA 
and added an excess of heparin (50 µM) to see whether the heparin was capable of 
exchanging with the RNA.  When analyzed by UV-Vis we found that the heparin had 
substantially removed the poly(A) RNA, as the majority of the RNA was now found in 
the supernatant.  The poly(A) RNA removal was observed for fibrils of either K18 
(Figure 4.12A) or K19 (Figure 4.12D).  We next wanted to determine whether the 
removal of RNA through the addition of heparin had any effect on the integrity of the 
fibril.  If heparin were removing RNA, possibly through replacement, it is possible that 
structural disturbances or general change in aggregate morphology would be observed.  
By EM we analyzed fibrils of K18 before (Figure 4.12B) and after (Figure 4.12C) the 
addition of heparin and found that the integrity of the tau aggregates was still upheld, 
with no changes in the fibrillar morphology detected.  The same structural adherence was 
also observed for fibrils of K19 with and without the addition of heparin (Figure 4.12 
E,F).  
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Figure 4.12:  Removal of RNA by the addition of heparin.  The removal of RNA was 
determined after the addition of heparin for K18 (A) and K19 (B) fibrils.  Poly(A) RNA 
found in the supernatant was analyzed by UV absorbance at 260 nm. All values in 
represent mean ± s.d. (n = 3 experiments). EM images were taken of sample before and 
after the addition of heparin.  For K18 fibrils, (B), before and (C) after heparin addition.  
For K19 fibrils, (E) before, and (F) after addition of heparin.  Bar = 400 nm. 
 
The addition of heparin to fibrils formed with poly(A) RNA resulted in the 
dissociation of RNA from the fibrils.  It could be assumed that the heparin removal 
occurred via the exchange of heparin bound to the fibril.  However, when heparin was 
added to remove the RNA (Figure 4.12), it was not clear whether the heparin was binding 
and taking the place of the RNA.  To test whether heparin exchanges with RNA on the 
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fibril we utilized heparin conjugated with fluorescein.  When fluorescent heparin (15 µM) 
was added to fibrils formed with RNA, the RNA was shown again to be removed (Figure 
4.13A,B).  The fluorescent heparin was also accounted for in the pellet and supernatant 
samples, with the majority of the heparin found to be in the pellet (Figure 4.13C,D).  For 
both K18 and K19 fibrils the addition of heparin therefore resulted in the removal of the 
RNA from the fibrils and the binding of the heparin.  From these sedimentation 
experiments it is clear that heparin added to the fibrils exchanges with the RNA. 
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Figure 4.13:  Exchange of RNA for heparin.  Fluorescein-conjugated heparin was 
added to poly(A) RNA/tau fibrils.  RNA in the pellet and supernatant after addition of 
heparin was assessed by Abs 260 nm, for (A) K18 and (B) K19 fibrils.  After exchange 
heparin bound to fibrils was determined by heparin found in the pellet and supernatant 
(Abs at 490 nm) for (C) K18 and (D) K19 fibrils.  All values represent mean ± s.d. (n = 3 
experiments). 
 
4.8.2 Cofactor exchange by anisotropy analysis 
To determine the binding of heparin by an alternative assay we devised a 
fluorescence anisotropy experiment.  The binding of heparin in solution to large fibrils 
would be expected to reduce the mobility of the heparin, which could be observed as a 
decrease in the rate of tumbling, resulting in an increase in the fluorescence anisotropy.  
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When the heparin fluorophore is excited with vertically polarized light the anisotropy r 
can be determined by measuring the intensities of the vertical (IVV) and horizontal (IVH) 
emissions of the fluorophore and applying the equation  
 
   
       
         
            (1) 
 
Polarization biases introduced by the instrument—for example due to biases in 
monochromators to transmit vertical versus horizontal emissions— can be accounted for 
by applying the G factor (125-127), or grating factor.  The determination of the G factor 
requires the excitiation of the fluorophore with horizontally polarized light and the 
measurement of the resulting vertical (IHV) and horizontal (IHH) emissions.  The G factor 
is described as 
   
   
   
          (2) 
 
Applying G factor to anisotropy gives 
   
        
          
            (3)  
 
We measured the anisotropy of fluorescent heparin for three-hundred seconds and added 
poly(A) RNA/tau fibrils and observed the change in anisotropy.  Both fibrils of K18 and 
K19 caused large increases in the anisotropy (Figure 4.14A,B) indicating the binding of 
the heparin to the RNA fibrils.  In studies focusing on the interaction between tau and 
cofactors, it was shown that cofactors bind to tau monomer (97, 98).  To ensure that the 
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large increases in anisotropy observed when adding fibrils to heparin were not caused by 
binding to tau monomers contained in the fibril mixture, we also performed experiments 
where tau monomer alone was added to fluorescent heparin.  Conservatively, we added 
the same concentration of tau monomer that our fibrils contained.  When monomer was 
added to K18 fibrils an increase in the anisotropy occurred (Figure 4.14C), but was 
marginal compared to adding fibrils to heparin.  When adding the same concentration of 
K19 monomer to the heparin the anisotropy increased (Figure 4.14D), but was 
significantly less than the anisotropy change when K18 monomer was introduced.   
 Together our results show that cofactors are incorporated into tau fibrils.  
Furthermore, the binding of a cofactor to the fibril is not a static event, as we have shown 
that cofactor exchange on the fibril can occur.  These findings are important as they 
indicate that the cofactor is not only important for nucleation and growth, but is also a 
component of the fibril. 
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Figure 4.14:  Heparin binds to tau fibrils as shown by fluorescence anisotropy.  The 
fluorescence anisotropy of fluorescein-conjugated heparin was monitored before and 
after the addition of tau fibrils.  (A) Addition of K18 poly(A) RNA fibrils after 300 
seconds.  (B) Addition of K19 poly(A) RNA fibrils after 300 seconds.  In control 
experiments tau monomers were added to heparin, (C) K18 and (D) K19.  Final 
concentrations of heparin and tau fibrils were 250 nM and 6 µM, respectively.  All values 
represent mean ± s.d. (n = 3 experiments). 
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Chapter Five: Amplification of tau fibrils using PMCA 
5.1 Seeding efficiency is dependent on seed concentration 
From our seeding experiments we have shown that we can rapidly propagate tau 
fibrils when providing tau monomer and cofactor for recruitment.  The efficiency of 
monomer recruitment is dependent on the concentration of fibril seeds introduced.  When 
seeding K18 and K19 monomer with respective fibrils, we observed an acceleration in 
the reaction kinetics when increasing the concentration of fibril seeds (Figure 3.3).  In 
order to further assess the efficiency of aggregation we applied a broad set of seed 
concentrations and monitored the recruitment of monomer by thioflavin T fluorescence.  
Htau40 monomer was seeded with non-sonicated fibril seeds of K18 WT, with molar 
seed concentrations ranging from 0.1% to 8% seed (Figure 5.1).  After the addition of 
seeds the reactions were sonicated for 5 seconds (in bath) and after 6 hours of incubation 
the efficiency of the reactions was determined.  Our data indicate that the efficiency of 
aggregation drastically decreases with decreasing seed concentration.  After accounting 
for fluorescence intensity contributions of introduced seeds we observed that the seeding 
capacity was limited at 0.1% seeds.  At 0.1% seeds the aggregation of monomer was 
nearly indistinguishable from samples without seeds (monomer only controls).    
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Figure 5.1:  Seeding of tau monomer with varying seed concentrations.  Various 
concentrations of K18 WTseeds were added to recruit monomeric tau.  Htau40 WT 
monomer (10 µM) was incubated with seeds and 5 µM thioflavin T (ThT) for 6 hr.  
Fluorescence emission was measured at 480 nm, with an excitation of 440 nm.  Heparin 
was included in all reactions at concentrations of 40 µM, except for samples of “ThT 
only” (Thioflavin T only).  All values represent mean ± SEM (n = 4 experiments).   
 
5.2 Fibril amplification concept 
We have shown that small amounts of fibril seeds added to monomeric tau are 
capable of recruiting the monomer into the fibril.  However, when seed concentrations 
are too low the seeding capacity is lost and the conversion of monomer to fibril does not 
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occur within the time period-frame of the experiment.  In the prion field a protein 
misfolding cyclic amplification (PMCA) assay that amplifies minute concentrations of 
misfolded prion amyloid has been developed (109).  The basis for the assay includes the 
alternation of fibril growth and breakage cycles that are applied to amplify undetectable 
concentrations of fibrils.  As we have also witnessed a limitation in the seeding capacity 
at a lowered seed concentration (0.1%) for tau fibrils, we asked whether the principles of 
PMCA could be applied to amplify tau fibrils previously undetectable.  We designed an 
experimental setup to amplify tau fibrils that utilizes a similar apporach as is used for 
prion amplification.  The sequence includes the introduction of minute concentrations of 
tau fibrils as seeds to monomer, and the subsequent sonication and incubation to amplify 
the fibrils.  The sonication is applied to break the fibrils and create additional fibril ends, 
onto which monomeric tau can grow.  The prolonged incubation phase allows for the 
time needed for the elongation of the fibrils to occur through the recruitment of 
monomer.  As a result of multiple cycles of breakage and elongation (Figure 5.2), an 
initially low and undetectable fibril seed concentration can be amplified through 
propagation to a fibril concentration that is then detectable.   
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Figure 5.2:  PMCA applied to tau fibrils.  Tau fibril seeds (blue arrows) are introduced 
to tau monomer.  Initial fibrils are propagating by undergoing alternating cycles of 
growth (incubation) and breakage (applied sonication).  At the end of multiple cycles of 
PMCA, an initially low concentration of fibril seeds has been amplified. 
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5.3 Fibril amplification of tau fibrils 
In collaboration with Virginia Meyer, the PMCA concept was applied to tau 
fibrils.  To test the PMCA concept on the amplification of tau fibrils we added K18 fibril 
seeds (initially unsonicated) at a concentration of 0.1% to htau40 WT monomer.  This 
concentration was chosen because a seeded reaction after 6 hours was shown to result in 
a minimal amount of monomer aggregation (Figure 5.1).  As before, we used the 
thioflavin T assay for the determination of fibrillar aggregation.  The seeded reactions 
underwent 12 cycles of PMCA, with a 5 second sonication pulse, followed by a 30 
minute incubation time, giving a total elapsed time of 6 hours.  At 4 cycles, 8 cycles and 
12 cycles samples were measured by fluorescence (Figure 5.3A), which showed that with 
successive cycles the aggregation of monomer increased.  Importantly, to rule out the 
occurrence of monomer aggregation through nucleation, we included a monomer control 
that contained no added seeds (monomeric tau was ensured by applying chemical 
denaturant) and was carried out through the 12 cycles of PMCA.  As this monomer 
control did not aggregate, it is evident that the aggregation enhancement imparted by 
PMCA cycles is due to the amplification of the initial fibril seed added.  Additionally, 
thioflavin T alone after 12 cycles of PMCA did not result in an increased fluorescence 
intensity (Figure 5.3A).   
To compare seeded reactions with PMCA reactions we sonicated the seeded 
reaction for 5 seconds and measured the growth after 6 hours of incubation—the same 
incubation time elapsed after 12 cycles of PMCA.  As was expected a single pulse of 
sonication was not sufficient to effectively promote the aggregation of the monomer 
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(Figure 5.3B).  The proposed mechanism of propagation by which PMCA amplifies a 
dilute concentration of fibril seed is suggested to occur not due to the total time the 
reaction undergoes sonication, but due to the periodic pulses of sonication (breakage) that 
are spaced between steps incubation (growth).  To test whether the periodicity of 
sonication was important for fibril amplification we applied an initial sonication pulse of 
60 seconds (total sonication time for 12 cycles of PMCA) to the seeded reaction and 
allowed the reaction to incubate for 6 hours.  As was expected the reaction did not result 
in a substantial amount of aggregation of the monomer (Figure 5.3B), in agreement with 
the idea that PMCA functions to promote fibril amplification due to applied cycles of 
sonication and incubation.  After the reactions were completed identical samples were 
pooled, sedimented and analyzed by SDS PAGE to verify the findings observed using the 
thioflavin T assay.  As was observed using the thioflavin T fluorescence assay, seeded 
reactions undergoing 12 cycles of PMCA resulted in the aggregation of the monomer.  
Control samples, to which no seeds were added, did not result in the aggregation of 
monomer after 12 PMCA cycles.  When applying 5 second and 60 second pulses to 
seeded samples and incubating for 6 hours, there was a minimal amount of aggregated 
monomer, which is consistent with the marginal fluorescence increases observed with the 
thioflavin T assay.  Together, the thioflavin T fluorescence assay and fibril sedimentation 
experiments reveal the efficacy of applying PMCA to amplify tau fibrils. 
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Figure 5.3:  PMCA applied to tau fibrils.  Htau40 WT (10 µM) underwent PMCA with 
the addition of 0.1% K18 WT seeds with 40 µM heparin. (A)  ThT fluorescence of 
htau40 WT with no seeds (12 PMCA cycles) and 4, 8, and 12 PMCA cycles with the 
addition of 0.1% seeds.  ThT was present in all reactions at 5 µM.  (B)  Samples were 
sonicated continuously for 5 seconds (duration of 1 sonication step of PMCA) and 60 
seconds (duration of combined 12 cycles of PMCA sonication), and then incubated for 6 
hours.   Samples undergoing 12 cycles, with and without seed addition are shown for 
comparison.  (C)  SDS PAGE of sedimented fibrils at the end of 12 PMCA cycles (or 6 
hours). All values represent mean ± SEM (n = 8 experiments).   
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5.4 Sensitivity of PMCA  
We had demonstrated the efficacy for PMCA applied to tau fibrils when using 
0.1% K18 fibrils as seeds and performing 12 cycles of PMCA.  Next we wanted to assess 
the sensitivity of PMCA to determine whether seeds further diluted could be amplified.  
We seeded htau40 WT monomer with fibril seeds of K18 ranging from 0.1% to 
0.00001% of monomer tau concentration and applied 40 cycles of PMCA.  Interestingly, 
at all the seed concentrations tested we observed amplification, with decreasing 
amplification occurring with each seed dilution.  Notably, the control for no seeds added 
did not result in any aggregation after 40 PMCA cycles.  As was expected, ThT only and 
0.01% seeds (seeds only) also did not result in elevated fluorescence (Figure 5.4A).  
When observing PMCA reactions substantial variability is observed between identical 
samples (Figure 5.5).  Emission spectra of thioflavin T indicate that the variability in 
amplification can arise, sometimes deviating due to a single reaction (e.g. see reaction in 
well B1).  It is possible that this variability originates due to an uneven force distribution 
in the bath.  If PMCA were to be applied as an assay for the accurate determination of tau 
fibrils, the variability would need to be accounted for when determining the number of 
trials chosen.  In summary, the results indicate that tau fibrils can be amplified, even 
when diluted by several orders of magnitude. 
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Figure 5.4:  Amplifying K18 fibrils at dilute seed concentrations.  Reactions 
underwent 40 cycles of PMCA (or 20 hours of incubation), and aggregation efficiency 
was determined by thioflavin fluorescence (thioflavin T present in reactions at 5 µM).   
(A) Varying initial seed concentrations of K18 fibrils from 0.1 to 0.00001% per mole of 
monomer (10 µM).  Control reactions were performed with 10 µM htau40 WT monomer 
and underwent 40 PMCA cycles without added seeds (no seeds).  (B)  Samples with 
added heparin (40 µM) and no added heparin were compared for effect of cofactor.  The 
influence of periodic sonicating was determined by applying 5 seconds and 200 seconds 
of sonication (1 cycle and 40 cycles of PMCA, respectively) and incubating samples for a 
total duration equivalent to of 40 cycles of PMCA (20 hours).  All values represent mean 
± SEM (n = 8 experiments).   
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Previously we had demonstrated arequirment of a cofactor for fibril propagation 
when carrying out seeded reactions.  In all the PMCA experiments thus far the cofactor 
heparin was included in the reactions.  As fibril breakage and elongation are the basis for 
PMCA we would expect that the omission of cofactor from the reactions would inhibit 
PMCA by reducing the efficiency of the elongation phase.  When comparing PMCA 
reactions using the same seed concentration, but with and without added heparin (40 
µM), we observed a substantial decrease in the amplification for reactions without added 
heparin (Figure 5.4B).  It should be noted that when introducing the seeds a low 
concentration of heparin (1.6 µM) is carried over to the reaction, which would account 
for the minor amplification observed for the “no heparin reaction”.  Again, we tested 
whether the amplification of the fibrils was occurring in part due to the periodic 
incubation cycles and not solely due to the incubation phase.  When sonicating for one 
cycle (5 seconds) there was only slight aggregation observed.  When sonicating for the 
total duration of 40 PMCA cycles (200 seconds) at the beginning of the reaction there 
was no substantial aggregation observed, further indicating that PMCA occurs due to the 
periodic breakage of fibrils in between incubation phases.  Our results reiterate the 
dependence of fibril elongation on the presence of a cofactor and validate that the 
mechanism of PMCA is based on cycles of combined breakage and growth of fibrils. 
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Figure 5.5:  Variability of PMCA.  Variability of ThT spectra after 40 cycles of PMCA 
using K18 fibrils as seeds and htau40 WT as recruited monomer.  Spectra were obtained 
in a 96-well plate (n = 8).  A1-A8 = 0.1% K18 seeds; B1-B8 = 0.01% seeds; C1-C8 = 
0.001% seeds; D1-D8 = 0.0001% seeds; E1-E8 = 0.00001% seeds; G1-G8 = no seeds; 
A11-H11 = 0.01% seeds (no heparin); A12-H12 = 0.01% seeds only.  Excitation = 440 
nm, Emission = 450nm -530 nm. 
  
5.5 Seeding with full-length seeds 
In all of our seeding reactions thus far we used K18 fibrils (unfractured) as initial 
seeds and propagated the fibrils by recruiting htau40 WT monomer.  In order to 
determine whether fibrils of htau40 WT could be propagated when htau40 WT fibrils 
were used as seeds we performed 40 cycles of PMCA with concentrations of 0.1% to 
0.00001% htau40 WT seeds.  As was seen when using K18 seeds, htau40 seeds could be 
effectively propagated, even to some extent when using the lowest seed concentration 
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tested (0.00001%) (Figure 5.6A).  Also, we again assessed the impact of omitting 
cofactor, and found that without added heparin the reaction efficiency was significantly 
reduced (Figure 5.6B).  Furthermore, the importance of applying sonication periodically 
to break the fibrils was again demonstrated as reactions with sonication applied only at 
the beginning of the reaction did not result in effective amplification (Figure 5.6B).  
These results indicate that like fibrils composed of K18 tau, htau40 fibrils are capable of 
being amplified.   
Next, we asked whether 3R tau could be amplified by PMCA.  Using htau23 as 
monomer and htau23 fibrils (unfractured) as seeds we assessed the amplification 
sensitivity (Figure 5.7A).  After 40 PMCA cycles we observed amplification compared to 
that contained monomer but no seeds; however the seed concentration amplified was 
limited to 0.001%.  The addition of cofactor was again shown to enhance amplification, 
as reactions with no added cofactor were amplified to a significantly lower extent (Figure 
5.7B).  Thus it is clear that fibrils composed of truncated tau, as well as fibrils of full-
length tau (either htau40 or htau23), are capable of being amplified. 
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Figure 5.6:  Amplifying htau40 fibrils.  Reactions underwent 40 cycles of PMCA (or 20 
hours of incubation) with 10µM htau40 WT monomer, and aggregation efficiency was 
determined by thioflavin fluorescence (thioflavin T present in reactions at 5 µM).   (A) 
Varying initial seed concentrations of K18 fibrils from 0.1 to 0.00001% per mole of 
monomer (10 µM).  Control reactions with 10 µM htau40 WT monomer underwent 40 
PMCA cycles without added seeds (no seeds).  (B)  Samples with added heparin (40 µM) 
and no added heparin were compared for effect of cofactor.  Influence of periodic 
sonicating was determined when applying 5 seconds and 200 seconds of sonication (1 
cycle and 40 cycles of PMCA, respectively) and incubating samples for total duration of 
40 cycles of PMCA (20 hours).  All values represent mean ± SEM (n = 8 experiments).   
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Figure 5.7:  Amplifying htau23 fibrils.  Reactions underwent 40 cycles of PMCA (or 20 
hours of incubation) with 10 µM htau23 WT monomer, and aggregation efficiency was 
determined by thioflavin fluorescence (thioflavin T present in reactions at 5 µM).   (A) 
Varying initial seed concentrations of K19 fibrils from 0.1 to 0.00001% per mole of 
monomer (10 µM).  Control reactions with 10 µM htau23 WT monomer underwent 40 
PMCA cycles without added seeds (no seeds).  (B)  Samples with added heparin (40 µM) 
and no added heparin were compared for effect of cofactor.  Influence of periodic 
sonicating was determined when applying 5 seconds and 200 seconds of sonication (1 
cycle and 40 cycles of PMCA, respectively) and incubating samples for total duration of 
40 cycles of PMCA (20 hours).  All values represent mean ± SEM (n = 8 experiments).   
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Chapter 6: Discussion 
6.1 Seeding of 3R and 4R tau 
There have been three distinct types of fibrils identified based on the composition 
of 3R and 4R tau (3R fibrils, 4R fibrils, and 3R/4R fibrils).  Studies have revealed that the 
core of these fibrils is composed of the microtubule binding repeats, and that -strands of 
the fibril are all arranged parallel with their side-chains in-register (60-62).  While the 
core of the fibrils and the -sheet stacking are conserved within compositionally distinct 
fibrils, structural variations could occur based on differences in the packing of -sheets 
within the fibril.  Such variations in the -sheet packing would therefore impart 
conformational differences among fibrils, and would be expected to alter biophysical 
properties.  The results of our seeding experiments have shown that key differences exist 
between the identified fibril types, and indicate that the fibrils are conformationally 
distinct.  Our findings show that 3R tau fibrils, as well as mixed 3R/4R fibrils, seed both 
3R and 4R tau.  Fibrils of 4R tau, however, seed 4R tau, but not 3R tau indicating an 
asymmetric barrier exists between 3R and 4R tau.  When 4R tau was first seeded with 3R 
tau fibrils, 3R tau was then capable of being seeded by 4R tau fibrils, indicating that a 
new conformation of 4R tau fibrils had been produced and further instilling the idea that 
fibril propagation proceeds by a templated mechanism.  Based on seeding properties, we 
have demonstrated the occurrence of four conformationally distinct fibrils—which 
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include 3R fibrils, 3R/4R fibrils, and two conformations of 4R fibrils (one that seeds 3R 
tau and one that does not) 
In our seeding experiments we have utilized truncated constructs K18 and K19 
that contain the microtubule binding repeat region and omit the N and C termini.  These 
truncated versions of tau are reflective of the protease resistant core region of fibrils 
found in Alzheimer’s disease.  Similar to constructs K18 and K19, this protease resistant 
core of Alzheimer’s disease fibrils is composed of around 100 amino acids, and includes 
most of the microtubule binding repeat region (73).  Additionally, the truncation of tau 
through proteolysis is observed in fibrils found in disease (128, 129) and has been linked 
as a precursor towards the aggregation of tau into NFTs (130)—despite other findings 
disputing this requirement (131).  Furthermore, tau that has been truncated at the C and N 
termini beyond the microtubule repeat region has been shown to assemble into fibrils 
more quickly and efficiently than full-length tau (129), and is capable of nucleating the 
aggregation of full-length tau (132).  Our findings indicate that fibrils composed of 
truncated constructs K18 and K19 effectively seed both truncated and full-length tau.  As 
the seeding properties observed were the same whether truncated or full-length constructs 
were used, it would be expected that the region of the protein outside the fibril core may 
not have any marked contributions to the fibril conformation. This would be in line with 
the flanking regions forming an intrinsically disordered coat (74, 75). 
The diversification of amyloid fibrils is well documented in prions, and is 
reflected by strain variations in both mammals and yeast (133-136).  The basis of distinct 
prion strains is considered to originate from conformational differences between fibrils 
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(137).  When monomeric protein is assembled onto the prion fibril, the conformation of 
the fibril is adopted in a templated manner through seeded aggregation (137, 138).    
Proteins that contain sequence variation, either between species or due to polymorphisms 
within a species, may also be recruited by prions if common permissible conformations 
exist (139).  In cases where sequence variation between fibril and monomer prevents a 
monomer from being recruited, transmission of the misfolded prion protein is prevented 
and a barrier between divergent sequences exists (138).  Transmission barriers in prions 
have been observed between species and can be introduced by minor mutations (137).  
The incompatibility of cross-seeded aggregation between sequences with minor 
differences is not limited to prions but includes other amyloids as well.  Amyloids formed 
by sequences of the OsmB membrane associated protein were  shown to be capable of 
seeding monomer of the same sequence, but not monomers with subtle sequence 
variations (140).  Fibrils of α-synuclein are capable of seeding the growth of monomeric 
α-synuclein, but are not capable of seeding - and -synuclein, despite having a 
substantial sequence homology (141).  Additionally, barriers between lysosome fibrils 
have also been demonstrated between species (142).  In our experiments that cross-seed 
3R tau with 4R tau we demonstrate the existence of a barrier similar to what has been 
observed for other amyloids.  The barrier was proven to be robust, as even a 5-fold 
addition (15%) of 4R fibril seeds did not allow for the recruitment of 3R tau monomer.  
To verify the seeding properties between 3R and 4R tau we utilized several experimental 
approaches.  From our kinetics experiments, using the intrinsic reporter acrylodan and the 
extrinsic fluorophore thioflavin T, as well as by electron microscopy and fibril 
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sedimentation experiments we found that 3R tau does not assemble on 4R tau fibril seeds.  
The seeding properties we observe in the in vitro experiments are also in agreement with 
cellular studies that focused on the aggregation induced by fibril seeds.  When 4R tau 
fibril seeds were transfected into cells overexpressing 4R tau, the monomer was observed 
to aggregate. However, transfected 4R tau fibrils into cells overexpressing 3R tau did not 
result in the aggregation of the endogenous tau (49).  Despite containing a majority of the 
4-repeat sequence, the lack of 30 amino acids leads to an incompatibility for 3R tau 
recruitment by 4R tau fibrils.  Interestingly, we observed the ability of 4R tau to be 
competent for the recruitment by 3R fibril seeds.  This is in agreement with Clavaguera et 
al. who showed that brain extracts from Pick’s disease—which contain aggregated 
deposits of predominantly 3R tau—were able to induce the formation of 4R tau in 
transgenic mice (55).    The cross-seeding asymmetry that we demonstrate is not the first 
observed between tau fibrils.  When studying the cross-seeding of fibrils composed of 
disease mutant P301L tau and wild-type tau, it was shown that fibrils of P301L are 
competent to seed P301L but not wild-type monomer.  Alternatively, fibrils composed of 
wild-type tau seed both wild-type and P301L tau, establishing an asymmetric barrier 
(143).   
Elongation of amyloid fibrils occurs through the subsequent addition of soluble 
protein.  The conformational influence that the fibril seed has on the conversion of 
monomer has been demonstrated in prions and reveals that the seed conformation is 
imprinted onto the assembling monomer.  The robustness of the templating nature was 
tested when distinct prion strains were propagated through multiple steps, with the 
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resulting fibrils maintaining the strain identity of the initial seed (144).  Conformational 
variation is implicit in prion amyloids and is manifested in the prion seeding properties.  
Prions composed of the same protein sequence can have different conformations, which 
may diverge in the ability to recruit a given sequence of monomer (145).  When cross-
seeding prions of different species, variations in sequence can prevent adoption of the 
misfolded conformer from one species to another.  For instance, an asymmetric seeding 
barrier was observed between mouse and Syrian hamster prions that allowed the hamster 
fibrils to seed mouse, but prevented mouse fibrils from seeding hamster.  When mouse 
monomer was seeded with hamster fibrils the resulting mouse fibrils were then capable of 
seeding mouse monomer (138).  The circumvention of the transmission barrier between 
mouse fibrils and hamster monomer through the templating of mouse monomer on 
hamster fibrils resulted in the emergence of a new conformation of mouse fibril.  From 
the seeded growth, mouse monomer was found to assume the conformation of the 
hamster fibrils (137).   
We had hypothesized that the same principles governing the propagation of prion 
conformation could be applied to tau fibrils.  In our experiments we analyzed the seeding 
properties of 3R and 4R tau and observed an asymmetric barrier, similar to what was 
shown to exist between mouse and hamster prions.  This observation provided the 
opportunity to assess the parallels between tau and prion fibrils with respect to a common 
conformational templating mechanism.  When growing 4R tau monomer on 3R tau 
fibrils, the 4R tau assumed the 3R tau fibril conformation and the resulting fibrils 
permitted the recruitment of 3R tau monomer.  Importantly, when multiple steps of 
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propagation were performed to remove the initial 3R tau seed, the 3R tau seeding 
properties were maintained within the 4R tau fibrils as indicated by the ability of the 
templated 4R tau fibrils to seed 3R tau.  This finding was important as it indicates that tau 
and prion fibrils propagate via a common mechanism despite sharing no similarity in 
sequence.  In view of our findings it would be interesting to determine whether the barrier 
observed preventing disease mutant P301L from seeding wild-type tau could be bypassed 
when templating P301L mutant monomer on wild-type tau seeds.   
The adaptation of the 4R tau monomer to the 3R tau fibril conformation indicates 
that the same sequence of tau is capable of assuming different conformations that possess 
variable seeding properties (i.e. one conformation that seeds 3R tau monomer and one 
that does not).  The ability of a tau sequence to assume variable conformations was also 
demonstrated by Frost et al., who observed that 4R tau grown on distinct fibril seeds 
produces different conformations (47).   The conformational diversity observed in tau 
fibrils is reminiscent of the strain phenomenon observed in prions. 
From our in vitro experiments we have identified at least four conformationally 
distinct fibrils based on the corresponding seeding properties (Figure 6.1).   Electron 
paramagnetic resonance spectroscopy studies that measure intramolecular distances 
within a fibril have indicated that the conformational basis of fibrils is even more 
complex, and that within a fibril sample multiple conformations can exist (63).  The 
effects of mutations, cofactors, chaperones, and post-translational modifications such as 
phosphorylation could also influence the conformational variability of tau fibrils.  In our 
experiments we have demonstrated the ability of tau fibrils to seed monomeric tau, 
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propagate, and diversify into different conformations.  We also identified the existence of 
conformational barriers that impart significant consequences on isoform recruitment.  As 
we have demonstrated that fibril seeds can act to provide nuclei to recruit monomeric tau, 
it is therefore expected that the initial nucleation events leading to aggregation would 
have a profound effect on the subsequent fibril formation.  Nuclei that contain both 3R 
and 4R tau, as was previously demonstrated (62), could be relevant to Alzheimer’s 
disease, where all 6 isoforms are found to deposit (146).   Nucleation events of 4R tau 
could be reflective of what is observed in tauopathies like progressive supranuclear palsy, 
argyrophillic grain disease, and corticobasal degeneration, where 4R tau is found to 
deposit (41).  Based on our findings the preferential deposition of 3R tau in Pick’s disease 
could not be explained by a barrier that prevents 4R tau from growing on 3R tau fibrils, 
as we have demonstrated that 3R tau nuclei do seed 4R tau.  However, one explanation 
for the lack of 4R tau in Pick’s disease could be that another 3R tau fibril conformation 
exists that does not seed 4R tau.  Alternatively, it is possible that the inefficient growth of 
4R tau on 3R tau fibrils, as we observe, could leave the fibrils susceptible to cellular 
clearance.  Our findings presented here have provided basic insights into the molecular 
mechanisms responsible for tau fibril propagation.  Attributes of prions such as strain 
diversity, transmission barriers, and strain emergence are clearly inherent in tau fibrils, 
suggesting that similar phenomena might occur in tauopathies.   
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Figure 6.1:  Templated fibril growth of tau.  Monomers of 3R and 4R tau (top) can 
only grow onto the ends of 3R (square),  3R/4R (oval), and 4R fibrils (triangle and 
hexagon) if their sequence is compatible with the conformation of the seed (arrows).  
Structural incompatibility gives rise to a seeding barrier (crossed out arrow).  Two 
conformations are possible for 4R fibrils based on the capacity to seed 3R tau.  The 
conformations observed could be reflective of conformations in disease that would create 
preferences for isoform deposition. PID = Pick’s disease, AD = Alzheimer’s disease, PSP 
= progressive supranuclear palsy, CBD = corticobasal degeneration, AGD = argyrophilic 
grain disease. 
 
 
6.2 Tau cofactors bind and sustain fibril propagation 
6.2.1 Fibril core is retained with diverse cofactors 
The structural core of in vitro formed tau fibrils has been well characterized when 
utilizing the cofactor heparin to induce fibril formation (60-62, 147).  We have further 
analyzed the effects of alternative cofactors on the structure of tau.  Using the single-
stranded poly(A) RNA nucleic acid as a cofactor, we formed aggregates with tau spin-
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labeled in the third repeat, and observed single-line spectra by EPR at six different sites.  
Single-line spectra were also observed at sites labeled in the third repeat when using 
heparin (60, 62).  The single-line spectra indicate a close proximity among the spin-labels 
in the fibril.  Importantly, the distance constraint implicit by a single-line spectrum 
narrows the structure of the fibril core to stacked -sheeets that are parallel, with side-
chains positioned in-register.   
From our EPR analysis we observed that tau aggregates formed from poly(A) 
RNA are highly-ordered and contain a structural core containing the third repeat that is 
also found to exist in heparin induced fibrils.  The ability to promote parallel, in-register 
fibrils was also observed for other cofactors such as single-stranded pyrimidine RNA, 
double-stranded RNA, DNA, tRNA, RNA extracted from yeast, and polyglutamate.  We 
demonstrate that a diverse set of nucleic acids and peptide cofactors all produce fibrils 
with a structured third repeat, suggesting that the third repeat invariability remains 
structured.  This structural arrangement is therefore consistently conserved within tau 
fibrils and does not appear to vary according to the cofactor used.  The herein described 
secondary structure is not limited to tau fibrils, as parallel, in-register -sheet 
arrangements have also been found to be the structural basis of other amyloids (148-150). 
6.2.2 Seeding properties conserved using RNA as cofactor 
When using heparin as a cofactor to form fibrils we had previously determined 
the seeding properties of tau and observed an asymmetric barrier between 3R and 4R tau 
(120).  As the cofactor initiates the formation of fibrils through nucleation, we had 
speculated that alternative cofactors could produce different conformations of fibrils that 
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might be reflected in variations in the seeding properties of 3R and 4R tau.  The seeding 
properties of tau using poly(A) RNA as a cofactor did not deviate from experiments using 
heparin.  The consistency of the seeding properties of tau, even when using a different 
class of cofactor, suggests a robust nature of tau propagation according to isoform.  While 
the seeding properties remained unchanged when using a different cofactor, we cannot 
exclude that poly(A) RNA produces fibrils with conformations different from fibrils 
formed in the presence of heparin.  It still remains possible that utilizing alternative 
cofactors such as RNA could result in conformational variations that are manifested in 
differences in -sheet packing. 
The method for determining the seeding properties utilized our developed 
acrylodan conjugated assay.  The study of tau aggregation in the presence of nucleic acid 
cofactors is hampered by the inability to utilize the routinely employed thioflavin assay.  
Thioflavin T has been shown to bind to nucleic acids and produce enhancements in 
fluorescence (151) that could be mistaken for the detection of amyloids.  The use of the 
acrylodan assay in these experiments further demonstrates its utility for measuring tau 
aggregation. 
6.2.3 Cofactor promotes elongation of fibril 
Cofactors function to facilitate tau aggregation by promoting nucleation.  In our 
seeding experiments we introduced sonciated pre-formed fibril seeds that allow the 
nucleation phase of aggregation to be bypassed.  The introduction of seeds provides the 
nuclei needed for aggregation and leads to the recruitment of monomer to elongate the 
fibril.  When studying the in vitro aggregation of tau, cofactors can be employed to 
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induce fibril assembly.  However, it is difficult to differentiate fibril growth phases of 
nucleation and elongation.  As seeding experiments result in the elongation of the fibril, 
we were able to monitor fibril growth and determine whether the presence of a cofactor 
contributed a role in elongation.  From our multi-step seeding experiment we observed 
that the propagation of fibril seeds was sustained through successive seeded reactions 
only when a cofactor was provided.  This result suggests that the cofactor not only 
initiates the nucleation of tau aggregation, but once nucleated, also facilitates the 
elongation of the fibril.   Our kinetic experiments monitoring the seeded aggregation of 
tau also support this conclusion, as the addition of both seed and cofactor promoted the 
assembly of tau fibrils, while the addition of only the seed did not.  As incubating the 
same concentrations of tau and RNA within the same time-period did not result in 
aggregation we can eliminate the possibility that nucleation was occurring within the time 
period and confirm that the cofactor significantly promotes the elongation of the fibril.  
Our findings suggest that a “nucleation only” role for cofactors as proposed previously 
(102) can be excluded. 
Our results are in agreement with Zhu et al. who found that increasing the 
concentration of heparin (up to a 1 heparin to 1 tau molar ratio), leads to an acceleration 
in the growth phase of the aggregation kinetics.  Consisted with our findings, this 
observation suggested that heparin facilitates fibril elongation (99).  The effect of a 
cofactor on tau fibrils also parallels the cofactor contribution to prion amyloids.  When 
using RNA as a cofactor, Deleault et al. showed that the successive seeding of prion 
fibrils is sustained through the addition of cofactor, but lost when the cofactor is removed 
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(121).  While our experiments indicate that a cofactor promotes fibril elongation and 
sustains aggregation, it has been shown that fibrils can be formed with high 
concentrations of tau or at high temperatures without the presence of a cofactor (89, 124).  
Fibrils formed without cofactor could be expected to have conformations that deviate 
from fibrils formed in the presence of cofactor.  It is possible that fibril conformations 
nucleated without a cofactor may experience little or no reliance on a cofactor for the 
elongation of the fibril.   
6.2.4 Cofactor stabilizes fibrils through binding 
At an elevated temperature we demonstrated that fibrils could be formed with and 
without the addition of cofactor (124).  A ~20 nm blueshift in the acrylodan emission 
maximum after 80 minute incubation,indicated protein aggregation. The presence of 
fibrilar structures was confirmed by EM imaging.  When cooled, however, the fibrils 
formed without cofactor were found to dissociate, while the fibrils formed with added 
cofactor did not.  This observation indicated that the cofactor provides a role in 
stabilizing the fibril, preventing reversion to the initial monomeric state.  If the cofactor 
stabilizes the fibril then it could be expected that the cofactor would bind as an accessory 
component.  We formed fibrils with RNA as a cofactor and carried out sedimentation 
experiments to determine whether the RNA co-sedimented with the insoluble fibrils.  We 
observed that the majority of the RNA was found bound to the fibrils.  The interaction 
between the tau fibrils and the cofactor has been previously investigated, however, 
reports deviate on whether the cofactor binds and is therefore part of the fibril (100-102).  
Importantly, our results demonstrating the binding of cofactor to tau fibrils are in 
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agreement with observations of aggregated tau found in disease.  In NFTs found in 
Alzheimer’s disease, the abundance of glycosaminoglycans is well documented (152-
156), and glycosaminoglycans have furthermore been shown to be localized on the fibrils 
(155, 156).  The use of nucleic acids as cofactors, as we have utilized here, is also 
comparable to potential cofactors that would be found available in the cell.  The inclusion 
of RNA in NFTs has been shown to occur, which again suggests the occurrence of 
cofactor binding to fibrils in vivo (157).  The RNA found in NFTs was not characterized 
according to type (tRNA, mRNA, etc), but based on our findings we demonstrate an 
indiscriminant requirement for nucleic acids in the facilitation of tau aggregation.  As we 
have shown that poly(A), poly(U), poly(dA), poly(AU), tRNA, and RNA extracted from 
yeast all are capable of forming highly ordered aggregates, the potential cofactors in the 
cell are likely to be based more on availability than on specific structure.   
The observation that a broad class of polyanionic molecules facilitates the 
aggregation of the highly basic region of tau suggests that the binding event between tau 
and cofactor occurs through electrostatic interactions.  In reactions where tau was 
nucleated with the presence of a cofactor the application of elevated salt inhibited 
aggregation (105, 158).  If the electrostatic interactions occurring between tau and 
cofactor were limited to the nucleation phase, then elevated salt should not affect the 
elongation of the fibril.  When treating seeded reactions with elevated salt we observed 
the abolishment of fibril growth suggesting that the cofactor-tau interactions are not 
limited to nucleation events, but are also important for fibril elongation.  The prevention 
of fibril elongation is even expected, since we have shown that cofactors bind to fibrils.  
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Disrupting the electrostatic interactions by introducing high salt would therefore inhibit 
binding and prevent aggregation as was observed. 
6.2.5 Cofactor exchange on the fibril 
When using RNA as a cofactor to induce tau aggregation we have observed the 
incorporation of the cofactor into the fibrils.  As we had used truncated constructs 
containing the binding repeats, the binding event is likely to occur at or near the fibril 
core and not at the unstructured N- and C-termini.  We had asked whether the 
introduction of another cofactor could exchange the cofactor originally used for 
induction.  When heparin was incubated with fibrils with bound RNA, the co-
sedimentation of RNA with the insoluble aggregates no longer occurs, indicating the 
removal of the RNA from the fibrils had taken place.  The assumption that the RNA 
removal occurred through the exchange of heparin was verified when fluorescein 
conjugated heparin was used as the exchanging cofactor.  The dye-labeled heparin was 
found to cause the release of the RNA from the fibril and was found to be associated with 
the sedimented aggregates.   Also, the increase in the fluorescence anisotropy of the 
fluorescent heparin was observed with the addition of RNA induced fibrils, further 
confirming the effect of cofactor exchange.   
The observation that cofactors can exchange on the fibril is important, as it 
indicates that the binding of the cofactor to the fibril does not occur at a buried site, but 
instead binds at a region that would be accessible for cofactor exchange.  The cofactor 
therefore would be expected to bind on the surface of the fibril.  Based on tau fibril 
structure, the orientation of tau strands in the fibril would require side-chains to be 
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stacked on top of each other.  As the repeat region of tau fibrils is highly basic, the 
resulting fibril structure would require positively charged side-chains to be positioned in 
close proximity.  Specifically, in repeats two and three, where tau is highly structured, 
there are five and four lysines present, respectively, that would introduce charge 
repulsions between parallel stacked -strands.  The binding of the polyanionic cofactor 
could neutralize these repulsions and stabilize the fibril.  It would seem probable that the 
cofactor-tau binding occurs with the length of the cofactor polymer stretched along the 
long fibril axis, similar to what has been observed for DNA bound to α-synuclein fibrils 
(159).  In this manner the cofactor could act as a scaffold to bridge and neutralize the 
positive repulsions between multiple strands of tau.  As was shown by the replacement of 
RNA by heparin, cofactors are not bound statically, but are dynamic and can exchange on 
the fibril (Figure 6.2).  The binding of cofactor to tau could have significant implications 
for the fibril properties.  Namely, the decoration of fibrils by varying cofactors could 
affect the fibril surface and impart the ability to transfer between cells.  Proteoglycans 
have been shown to be distributed on the cell surface (160) and could be a means by 
which tau fibrils could transfer into cells.  Based on heparin exchange with RNA on the 
fibril, we have shown that tau fibrils can bind glycosaminoglycans through an exchange 
mechanism.  As proteoglycans have been shown to bind cationic ligands such as 
polypeptides and provide a role of endocystosis (161), it is possible that the same 
internalization mechanisms may be applied to tau fibrils.  In fact, cell surface heparan 
sulfate proteoglycans have recently been shown to facilitate the cellular binding and 
internalization of tau fibrils (162).  These findings further indicate the importance 
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inherent in the tau-cofactor association.  It is possible that cofactors bound to tau fibrils 
could exchange for proteoglycans on the cell surface, providing a mechanism for the 
internalization of tau fibrils into the cell, which ultimately could account for the 
spreading of the tau pathology. 
 
 
Figure 6.2:  Cofactor binding and exchange on the fibril.  The envisioned mode of 
cofactor binding is that a cofactor polymer such as poly(A) RNA could bind along the 
fibril and neutralize repulsive positive charges introduced from side-chain proximity 
between strands.  The introduction of a cofactor such as heparin can result in the 
exchange of the bound cofactor. 
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6.3 Tau fibril amplification by PMCA 
From our in vitro experiments we have demonstrated that we can transcend the 
limitations of low seed concentrations when carrying out seeded reactions of tau.  For the 
first time we have applied the principles of PMCA used to amplify prions towards the 
amplification of tau fibrils.  As shown by the thioflavin T assay, and verified by 
sedimentation of fibrils, we have successfully propagated fibrils whose concentration was 
shown previously to be too dilute for efficient seeded amplification.  Next, we assessed 
the sensitivity of seed dilution and found that we could amplify a concentration of seed 
diluted 10
4
 fold of what was found to be insufficient to recruit monomer effectively in a 
single sonication cycle seeded reaction (0.1% seed).  At this concentration (0.00001% 
seeds) tau in the fibrils is present at 10
8
 molecules ( 5 X 10
8
 molecules per mL), while the 
total tau monomer (10 µM) consists of 10
15
 molecules.  Whether we had used seeds of 
truncated (K18) or full-length (htau40) tau to amplify, similar sensitivity was observed.  
Htau40 WT was the recruited monomer in all of the experiments.  As truncated tau 
nucleates to form aggregates in a shorter time period than full-length tau (163, 164), we 
would not have been able to apply as many PMCA cycles before the monomer only (no 
seeds) negative controls would have begun to aggregate.  Therefore, by using htau40 
monomer to be recruited we were able to perform more cycles (40 cycles), and 
meanwhile avoid spontaneous nucleation.  Since the monomer only (no seeds) was never 
shown to aggregate during the 40 cycles, we can be confident that the fibril growth 
observed through the addition of seeds is not due in part to monomer nucleation, but 
solely to the elongation and propagation of the fibril seeds.  Induced aggregation of tau 
 110 
monomers is best promoted under conditions of low salt (0.1M NaCl) (158) and is aided 
by oxidizing conditions when native cysteines are present (96).  Additionally, full-length 
tau may take days to aggregate at low µM concentrations (4-50 µM) at 37 °C (96).  
Attention to the applied conditions is therefore important when considering the 
prevention of spontaneous nucleation of monomer.       
In the PMCA reactions carried out, the cofactor heparin was added.  When 
cofactor was not included we found that the amplification efficiency was drastically 
reduced, regardless of whether K18 or htau40 were used as seeds.  This finding was 
expected as we had previously shown that the addition of a cofactor was needed for the 
fibril propagation to be sustained.  Interestingly, when PMCA is applied to prion 
amyloids it has been shown that the fibril amplification is also dependent on the presence 
of a polyanionic cofactor (121, 165), further suggesting common requirements needed for 
growth of both tau and prion fibrils. 
The incubation and breakage (sonication) steps are believed to be the basis of 
amplification when PMCA is applied to prions.  In fact, PMCA applied to prions without 
the incubation steps (166) or without the sonication steps (109, 166, 167) results in a loss 
of amplification.  Similarly, we found that a reaction, in which the fibrils were only 
sonicated 1 cycle (5 seconds) and incubated for 20 hours were not substantially 
amplified.  Reactions in which all the sonication steps were carried out consecutively  
 (40 cycles, 200 seconds) and incubated for 20 hours also did not result in 
considerable amplification. This observation indicates the need for sonication steps to be 
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spaced between the incubation steps, in order to allow time for fibril elongation to occur 
before the next breakage step is induced. 
Our findings presented here indicate that PMCA can be applied to the 
amplification of dilute quantities of tau fibrils.  The function of this assay could 
ultimately be applied towards the amplification of tau fibrils derived from biological 
samples.  When applied to prions, PMCA has been used to quantitatively determine the 
concentration of prions within a sample.  Using animal models the PMCA assay has 
demonstrated a heightened sensitivity that allows for the detection of dilute prion 
concentrations in sources that include brain, blood, and urine (168, 169).  Similarly it is 
possible that PMCA could provide a diagnostic tool for the presence of tau fibrils found 
in comparable tissue and fluid samples.  We have taken the first important steps to 
optimize an assay and implement PMCA for the amplification of tau fibrils.  The utility 
of PMCA applied to tau fibrils is expected to support fundamental studies of fibrils 
derived from in vivo sources.  
6.4 Future work 
The described studies were performed using recombinant tau protein that was not 
phosphorylated.  As phosphorylation of tau is associated with disease, further studies are 
needed to elucidate whether phosporylation of tau is critical for the phenomena observed.  
For example, it is not known whether the seeding properties of tau fibrils are influenced 
by tau phosphorylation.  We observed that fibril propagation is dependent on the presence 
of a cofactor.  As phosporylation assists in the aggregation of tau (85), it will be 
important to determine whether phosporylated tau requires cofactors for template growth.  
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Finally, we have developed an assay for the amplification of tau fibrils.  Further 
optimization is needed to enhance its sensitivity and to adopt it for use in conjunction 
with in vivo derived material.  
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Appendix A: Tau constructs 
 
Repeat Region of tau 
 
 
 
MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG  60   
SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG  120  
HVTQARMVSK SKDGTGSDDK KAKGADGKTK IATPRGAAPP GQKGQANATR IPAKTPPAPK  180  
TPPSSGEPPK SGDRSGYSSP GSPGTPGSRS RTPSLPTPPT REPKKVAVVR TPPKSPSSAK  240  
SRLQTAPVPM PDLKNVKSKI GSTENLKHQP GGGKVQIINK KLDLSNVQSK CGSKDNIKHV  300  
PGGGSVQIVY KPVDLSKVTS KCGSLGNIHH KPGGGQVEVK SEKLDFKDRV QSKIGSLDNI  360  
THVPGGGNKK IETHKLTFRE NAKAKTDHGA EIVYKSPVVS GDTSPRHLSN VSSTGSIDMV  420  
DSPQLATLAD EVSASLAKQG L      
 
                                        
 
QTAPVPMPDLKNVKSKIGSTENLKHQPGGGK Repeat 1 
 
 
VQIINKKLDLSNVQSKCGSKDNIKHVPGGGS Repeat 2 
 
 
VQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQ Repeat 3 
 
 
VEVKSEKLDFKDRVQSKIGSLDNITHVPGGGN Repeat 4 
 
*cysteines found in repeat 1 and 2 
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Htau40 
 
MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG  60   
SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG  120  
HVTQARMVSK SKDGTGSDDK KAKGADGKTK IATPRGAAPP GQKGQANATR IPAKTPPAPK  180  
TPPSSGEPPK SGDRSGYSSP GSPGTPGSRS RTPSLPTPPT REPKKVAVVR TPPKSPSSAK  240  
SRLQTAPVPM PDLKNVKSKI GSTENLKHQP GGGKVQIINK KLDLSNVQSK CGSKDNIKHV  300  
PGGGSVQIVY KPVDLSKVTS KCGSLGNIHH KPGGGQVEVK SEKLDFKDRV QSKIGSLDNI  360  
THVPGGGNKK IETHKLTFRE NAKAKTDHGA EIVYKSPVVS GDTSPRHLSN VSSTGSIDMV  420  
DSPQLATLAD EVSASLAKQG L                                            441 
                                    Estimated pI = 8.24 
      M.W = 45850 
Htau23 
 
MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKAEEAGI GDTPSLEDEA     
AGHVTQARMV SKSKDGTGSD DKKAKGADGK TKIATPRGAA PPGQKGQANA TRIPAKTPPA   
PKTPPSSGEP PKSGDRSGYS SPGSPGTPGS RSRTPSLPTP PTREPKKVAV VRTPPKSPSS   
AKSRLQTAPV PMPDLKNVKS KIGSTENLKH QPGGGKVQIV YKPVDLSKVT SKCGSLGNIH    
HKPGGGQVEV KSEKLDFKDR VQSKIGSLDN ITHVPGGGNK KIETHKLTFR ENAKAKTDHG   
AEIVYKSPVV SGDTSPRHLS NVSSTGSIDM VDSPQLATLA DEVSASLAKQ GL     
 
Estimated pI = 9.38 
      M.W = 36760  
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K18 Construct 
 
MQTAPVPMPD LKNVKSKIGS TENLKHQPGG GKVQIINKKL DLSNVQSKCG SKDNIKHVPG   
GGSVQIVYKP VDLSKVTSKC GSLGNIHHKP GGGQVEVKSE KLDFKDRVQS KIGSLDNITH   
VPGGGNKKIE   
 
 
Estimated pI = 9.7 
M.W = 13813 
K19 Construct 
 
 
MQTAPVPMPD LKNVKSKIGS TENLKHQPGG GKVQIVYKPV DLSKVTSKCG SLGNIHHKPG   
GGQVEVKSEK LDFKDRVQSK IGSLDNITHV PGGGNKKIE   
 
                                    Estimated pI = 9.67 
      M.W = 10567 
                   
 
 
 
 
 
 
 
 130 
Appendix B: Tau purification 
 
Elution program and gradient profile 
       Mono S 10/100 
GL         
             
 Flow rate 
(ml/min)       3.0 
 Eluate fraction size (ml)     3.0 
 Linear gradient         
   Target concentration buffer B (%B)  60.0 
 
  Length of gradient (column volumes) 
1
           
11.0 
 
        
 
Linear gradient for cation exchange elution of tau.  Slope of increasing buffer B versus 
ml of eluate. 
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Htau40 WT cationic exchange elution profile 
 
Cationic exchange elution chromatograph for htau40 WT.  Absorbance at 280 nm shown 
in blue with the linear gradient shown in green.  Eluate fractions (3ml) shown at the 
bottom in red. 
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Htau40 WT gel filtration elution profile 
 
Gel filtration elution chromatograph of Htau40 WT.  Htau40 WT purified over Superdex 
200 medium packed column  
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Appendix C: PMCA setup 
 
Bath sonicator horn used for applied cycles of PMCA  
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PMCA reactions in 96-well plate with sample cover.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 135 
96-well plate with cover and plate lid.  Two transfer pipette bulbs were sealed and 
fastened to plate to allow for plate to float in bath sonicator. 
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Covered plate was allowed to float in bath sonicator while undergoing PMCA. 
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